

**Oral Posters**  
**Clinical**

**Su-OP01 A SET OF GENES EXPRESSED IN BREAST CANCER BONE METASTASES DISCLOSES PREDISPOSITION TO GENERATE METASTASES IN MULTIPLE ORGANS**

M. Capulli\*<sup>1</sup>, A. Angelucci<sup>2</sup>, N. Rucci<sup>1</sup>, F. Martella<sup>3</sup>, M. Bologna<sup>2</sup>, L. Ventura<sup>4</sup>, O. Moreschini<sup>5</sup>, S. Pelle<sup>5</sup>, K. Driouch<sup>6</sup>, T. Landemaine<sup>6</sup>, R. Lidereau<sup>6</sup>, P. Clement-Lacroix<sup>7</sup>, T. Garcia<sup>7</sup>, A. Teti<sup>1</sup>, E. Ricevuto<sup>3</sup>

<sup>1</sup>Department of Experimental Medicine, <sup>2</sup>Department of Basic Applied Biology, <sup>3</sup>U.O. Medical Oncology, University of L'Aquila, <sup>4</sup>Department of Pathology, San Salvatore Hospital, L'Aquila, <sup>5</sup>Orthopaedic and Traumatology Department, University of Rome "La Sapienza", Rome, Italy, <sup>6</sup>Oncogenetic Laboratory, Centre René Huguenin, Institut de la Santé et de la Recherche Médicale, St.Cloud, <sup>7</sup>Proskelia, a Galapagos Company, PROSTRAKAN, Romainville, France

**Su-OP02 NOVEL ASSOCIATION BETWEEN A POLYMORPHISM IN THE P2X7 RECEPTOR GENE AND LOSS OF LUMBAR SPINE BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN**

A. Gartland\*<sup>1</sup>, K. K. Skarrat<sup>2</sup>, L. J. Hocking<sup>3</sup>, R. Clifton-Bligh<sup>2</sup>, C. Parsons<sup>3</sup>, W. D. Fraser<sup>4</sup>, D. M. Reid<sup>3</sup>, J. A. Gallagher<sup>5</sup>, J. S. Wiley<sup>2</sup>

<sup>1</sup>School of Medicine and Biomedical Sciences, The University of Sheffield, Sheffield, United Kingdom, <sup>2</sup>Department of Medicine, University of Sydney at Nepean Hospital, Penrith, Australia, <sup>3</sup>Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, <sup>4</sup>School of Clinical Science, <sup>5</sup>School of Biomedical Sciences, The University of Liverpool, Liverpool, United Kingdom

**Su-OP03 EFFECTS OF COL1A1 POLYMORPHISMS AND HAPLOTYPES ON PERIMENOPAUSAL BONE MASS AND POSTMENOPAUSAL BONE LOSS**

N. Gonzalez-Bofill\*<sup>1</sup>, L. B. Husted<sup>1</sup>, P. Vestergaard<sup>1</sup>, C. L. Tofteng<sup>2</sup>, B. Abrahamsen<sup>3</sup>, P. Eiken<sup>4</sup>, B. L. Langdahl<sup>1</sup>

<sup>1</sup>Endocrinology, Århus University Hospital, Århus, <sup>2</sup>Endocrinology, Copenhagen University Hospital, Hvidovre, <sup>3</sup>Endocrinology, Copenhagen University Hospital, Gentofte, <sup>4</sup>Endocrinology, Hillerød Hospital, Hillerød, Denmark

**Su-OP04 FUNCTIONAL ROLE OF TNFSF11 GENE PROMOTER POLYMORPHISMS IN POSTMENOPAUSAL OSTEOPOROSIS**

S. Mencej\*<sup>1</sup>, O. M. E. Albagha<sup>2</sup>, J. Prezelj<sup>3</sup>, T. Kocjan<sup>3</sup>, J. Marc<sup>1</sup>

<sup>1</sup>Chair of Clinical Biochemistry, University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia, <sup>2</sup>Rheumatic Diseases Unit, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom, <sup>3</sup>Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre, Ljubljana, Slovenia

**Su-OP05 PROMOTER AND INTRON 1 POLYMORPHISMS OF COL1A1 PREDISPOSE TO OSTEOPOROSIS BY REGULATING TRANSCRIPTION AND ALTERING BINDING OF SP1, NMP4 AND OSTERIX**

H. Jin\*<sup>1</sup>, O. M. E. Albagha<sup>1</sup>, R. J. Van't Hof<sup>1</sup>, S. H. Ralston<sup>1</sup>

<sup>1</sup>Molecular Medicine Centre, University of Edinburgh, Edinburgh, United Kingdom

**Su-OP06 BOTH N- AND C-TERMINAL FRAGMENTS OF PARATHYROID HORMONE-RELATED PROTEIN (PTHrP) REVERSE THE CATABOLIC EFFECTS**

**OF 3-METHYLPREDNISOLONE ON BONE REGENERATION IN MICE.**

L. F de Castro\*<sup>1</sup>, D. Lozano<sup>1</sup>, E. Gómez-Barrena<sup>2</sup>, F. Manzarbeitia<sup>3</sup>, P. Esbrit<sup>1</sup>

<sup>1</sup>Bone and Mineral Metabolism Laboratory, <sup>2</sup>Traumatologic Department, <sup>3</sup>Pathology Department, Fundación Jimenez Díaz, Madrid, Spain

**Su-OP07 EFFECT OF VITAMIN-D3 AND CALCIUM ON FRACTURE RISK IN 65-71 YEAR OLD WOMEN IN A 3-YEAR RANDOMIZED CLINICAL TRIAL – PRELIMINARY RESULTS OF THE OSTPRE-FRACTURE PREVENTION STUDY**

K. T. J. Salovaara\*<sup>1</sup>, M. Tuppurainen<sup>2</sup>, T. Rikkinen<sup>1</sup>, M. Karkkainen<sup>1</sup>, J. Sirola<sup>1</sup>, R. Honkanen<sup>1</sup>, E. Alhava<sup>3</sup>, H. Kroger<sup>4</sup>

<sup>1</sup>Bone and Cartilage Research Unit, University of Kuopio, <sup>2</sup>Department of Gynecology and Obstetrics, University Hospital of Kuopio, <sup>3</sup>Department of Surgery, University of Kuopio, <sup>4</sup>Department of Orthopedics, Traumatology and Hand Surgery, University Hospital of Kuopio, KUOPIO, Finland

**Su-OP08 NON-OSTEOPOROTIC WEDGE DEFORMITY AND OSTEOPOROTIC VERTEBRAL FRACTURE IMAGED BY X-RAY ABSORPTIOMETRY IN PRE- AND POSTMENOPAUSAL WOMEN (OPUS STUDY)**

L. Ferrar\*<sup>1</sup>, G. Jiang<sup>1</sup>, D. M. Reid<sup>2</sup>, C. Roux<sup>3</sup>, D. Felsenberg<sup>4</sup>, C. Glueer<sup>5</sup>, R. Eastell<sup>1</sup>

<sup>1</sup>School of Medicine and Biomedical Science, University of Sheffield, Sheffield, <sup>2</sup>Dept of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom, <sup>3</sup>Centre d'Evaluation des Malades Osseuses, Rene Descartes University, Paris, France, <sup>4</sup>Centre of Bone and Muscle Research, Universitätsmedizin Berlin, Berlin, <sup>5</sup>Diagnostic Radiology, University Hospital Schleswig-Holstein, Kiel, Germany

**Su-OP09 EFFECT OF THYROID STATUS ON THE SKELETON IN POST-MENOPAUSAL WOMEN: THE OPUS STUDY**

E. Murphy\*<sup>1</sup>, C. Glueer<sup>2</sup>, D. M. Reid<sup>3</sup>, D. Felsenberg<sup>4</sup>, C. Roux<sup>5</sup>, R. Eastell<sup>6</sup>, G. R. Williams<sup>1</sup>

<sup>1</sup>Molecular Endocrinology, Imperial College London, London, United Kingdom, <sup>2</sup>Arbeitsgruppe Medizinische Physik, Universitätsklinikum Schleswig-Holstein, Kiel, Germany, <sup>3</sup>Medicine & Therapeutics, University of Aberdeen, Aberdeen, United Kingdom, <sup>4</sup>Zentrum Muskel & Knochenforschung, Freie & Humboldt Universität Berlin, Berlin, Germany, <sup>5</sup>Centre d'Evaluation des Maladies Osseuses, Hopital Cochin, Paris, France, <sup>6</sup>Academic Unit of Bone Metabolism, Northern General Hospital, Sheffield, United Kingdom

**Su-OP10 INFLUENCE OF MENARCHEAL AGE ON DISTAL TIBIA MICROSTRUCTURE IN 20-YEAR OLD AND PREMENOPAUSAL MIDDLE-AGED WOMEN**

T. Chevalley\*<sup>1</sup>, J. Bonjour<sup>1</sup>, S. Ferrari<sup>1</sup>, R. Rizzoli<sup>1</sup>

<sup>1</sup>Service of Bone Diseases, Department of Rehabilitation and Geriatrics, University Hospitals and Faculty of Medicine, Geneva, Switzerland

**Oral Posters**

**Basic**

**Su-OP11 ACTIVATION OF THE CANONICAL WNT SIGNALING PATHWAY INDUCES CHONDROCYTE DEDIFFERENTIATION**

R. L. Miclea\*<sup>1</sup>, E. C. Robanus-Maandag<sup>2</sup>, H. Bloys<sup>3</sup>, C. W. G. M. Löwik<sup>3</sup>, J. M. Wit<sup>1</sup>, M. Karperien<sup>4</sup>

<sup>1</sup>*Pediatrics*, <sup>2</sup>*Human Genetics*, <sup>3</sup>*Endocrinology*, Leiden University Medical Centre, Leiden,  
<sup>4</sup>*Institute for Biomedical Technology*, University of Twente, Enschede, Netherlands

**Su-OP12 MYOSTATIN DEFICIENCY INCREASES CORTICAL BONE FORMATION INDEPENDENT OF CHANGES IN GROUND REACTION FORCES DURING NORMAL LOCOMOTION**

M. W. Hamrick\*<sup>1</sup>, S. Ponnala<sup>1</sup>, A. Zumwalt<sup>2</sup>, D. Schmitt<sup>3</sup>

<sup>1</sup>*Cellular Biology and Anatomy, Medical College of Georgia, Augusta*, <sup>2</sup>*Anatomy, Boston University, Boston*, <sup>3</sup>*Biological Anthropology and Anatomy, Duke University, Durham, United States*

**Su-OP13 IN VITRO OSTEOCLASTOGENESIS AND BONE RESORPTION DURING SPACEFLIGHT**

R. Tamma<sup>1</sup>, G. Colaianni<sup>1</sup>, C. Camerino<sup>1</sup>, A. Di Benedetto\*<sup>1</sup>, G. Greco<sup>1</sup>, M. Strippoli<sup>1</sup>, R. Vergari<sup>1</sup>, A. Grano<sup>1</sup>, L. Mancini<sup>1</sup>, A. Zallone<sup>1</sup>

<sup>1</sup>*Human Anatomy and Histology, University of Bari, Bari, Italy*

**Su-OP14 MYELOMA CELL-INDUCED COLLAPSE OF THE VASCULAR BONE REMODELING COMPARTMENTS LEADS TO OSTEOLYSIS AND THE GENERATION OF OSTEOCLAST-MYELOMA HYBRID CELLS**

T. L. Andersen\*<sup>1</sup>, K. Søe<sup>1</sup>, T. E. Sondergaard<sup>1</sup>, K. Kupisiewicz<sup>1</sup>, T. Plesner<sup>2</sup>, J. M. Delaisse<sup>1</sup>

<sup>1</sup>*Department of Clinical Cell Biology*, <sup>2</sup>*Department of Hematology, Vejle Hospital, IRS-CSFU, Southern Denmark University, Vejle, Denmark*

**Su-OP15 CANCER STRESS AFFECTS TRANSCRIPTOME OF BONE CELLS: METASTASES AND MULTIPLE MYELOMA GENERATE DISTINCT TRANSCRIPTIONAL FOOTPRINTS IN OSTEOCYTES IN VIVO**

K. Ackermann\*<sup>1</sup>, S. Eisenberger<sup>1</sup>, W. Pyerin<sup>1</sup>

<sup>1</sup>*Biochemical Cell Physiology A135, German Cancer Research Center, Heidelberg, Germany*

**Su-OP16 IN VIVO AND IN VITRO BONE PHENOTYPE CHARACTERIZATION OF THE IMMUNODEFICIENT ADA-KO MOUSE**

A. V. Sauer\*<sup>1</sup>, E. Mrak<sup>2</sup>, E. Zacchi<sup>2</sup>, R. Jofra Hernandez<sup>1</sup>, A. Tabucchi<sup>3</sup>, A. Rubinacci<sup>2</sup>, A. Aiuti<sup>1</sup>

<sup>1</sup>*hsr-TIGET*, <sup>2</sup>*Bone Metabolic Unit, San Raffaele Hospital, Milan*, <sup>3</sup>*Institute of Biochemistry and Enzymology, University of Siena, Siena, Italy*

**Su-OP17 THE IKK INHIBITORS CELASTROL AND PARTHENOLIDE INHIBIT BREAST CANCER CELL PROLIFERATION AND MIGRATION IN VITRO AND OSTEOLYTIC BONE METASTASIS IN VIVO**

A. I. Idris\*<sup>1</sup>, H. Libouban<sup>2</sup>, H. Nyangoga<sup>2</sup>, E. Landao-Bassonga<sup>1</sup>, D. Chappard<sup>2</sup>, S. H. Ralston<sup>1</sup>

<sup>1</sup>*Rheumatology, University of Edinburgh, Edinburgh, United Kingdom*, <sup>2</sup>*Faculté de Médecine, INSERM, Angers, France*

**Su-OP18 TNF-RELATED APOPTOSIS INDUCING LIGAND (TRAIL) INHIBITS PRIMARY BONE TUMOR GROWTH AND AUGMENTS SURVIVAL IN A HUMAN MODEL EWING SARCOMA**

L. Geffroy<sup>1</sup>, D. Chauviere<sup>1</sup>, F. Lamoureux<sup>1</sup>, G. Picarda<sup>1</sup>, O. Delattre<sup>2</sup>, S. Burchill<sup>3</sup>, P. Delepine<sup>4</sup>, F. Gouin<sup>1</sup>, D. Heymann<sup>5</sup>, F. Redini\*<sup>1</sup>

<sup>1</sup>*EA 3822 - INSERM ERI 7, Faculté de Médecine, Nantes cedex 1*, <sup>2</sup>*INSERM U830, Institut*

Curie, Paris, France, <sup>3</sup>Leeds Institute of Molecular Medicine, St James Univ Hosp, Leeds, United Kingdom, <sup>4</sup>INSERM U613, Université de Bretagne occidentale, Brest, <sup>5</sup>EA 3822 - INSERM ERI 7, Faculté de Médecine, Nantes, France

**Su-OP19 SKELETON REGULATES PANCREATIC FUNCTION VIA BONE MORPHOGENETIC PROTEIN-6 (BMP-6)**

P. Simic\*<sup>1</sup>, L. Grgurevic<sup>1</sup>, I. Orlic<sup>1</sup>, A. Tikvica<sup>1</sup>, M. Zuvic<sup>2</sup>, S. Vukicevic<sup>1</sup>

<sup>1</sup>Laboratory for Mineralized Tissues, Department of Anatomy, <sup>2</sup>Department of Nuclear Medicine, School of Medicine University of Zagreb, Zagreb, Croatia

**Su-OP20 SILENCING LAMIN A/C DECREASES OSTEOBLAST DIFFERENTIATION AND STIMULATES OSTEOCLASTOGENESIS THROUGH ENHANCED RANKL SIGNALING**

M. Rauner\*<sup>1</sup>, W. Sipos<sup>2</sup>, R. Foisner<sup>3</sup>, L. Hofbauer<sup>4</sup>, P. Pietschmann<sup>1</sup>

<sup>1</sup>Institute of Pathophysiology, Medical University of Vienna, <sup>2</sup>II Medical Clinic, University of Veterinary Medicine, <sup>3</sup>Max F. Perutz Laboratories, Medical University of Vienna, Vienna, Austria, <sup>4</sup>Division of Endocrinology and Bone Diseases, Medical Faculty, Technical University of Dresden, Dresden, Germany

**Bone development and tissue engineering Su-P001 – Su-P018**

**Su-P001 DLK1/FA1 REGULATES THE CHONDROGENIC CONDENSATION AND EARLY CHONDROCYTE DIFFERENTIATION IN LIMB BUD MICROMASS CULTURES AND ITS EXPRESSION IS MODULATED BY TGF-BETA SIGNALING PATHWAY**

B. M. Abdallah\*<sup>1</sup>, L. M. Harkness<sup>1</sup>, M. Kassem<sup>1</sup>

<sup>1</sup>Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

**Su-P002 BONE MINERAL ACCRUAL AND GAIN IN SKELETAL WIDTH IN PRE-PUBERTAL SCHOOL CHILDREN IS INDEPENDENT OF THE MODE OF SCHOOL TRANSPORTATION – ONE-YEAR DATA FROM THE PROSPECTIVE OBSERVATIONAL PEDIATRIC OSTEOPOROSIS PREVENTION (POP) STUDY**

G. Alwis\*<sup>1</sup>, C. Linden<sup>1</sup>, M. Dencker<sup>2</sup>, S. Stenevi-Lundgren<sup>1</sup>, P. Gardsell<sup>1</sup>, M. Karlsson<sup>1</sup>

<sup>1</sup>Clinical and Molecular Osteoporosis research Unit, Department of Orthopaedics,

<sup>2</sup>Department of Clinical Physiology, Lund University, Malmö, Sweden

**Su-P003 STUDY OF THE LOCAL VARIATIONS IN TRABECULAR MICROSTRUCTURAL PARAMETERS OF PROXIMAL HUMAN FEMUR AND ITS RELATIONSHIP WITH BIOMECHANICAL PROPERTIES**

J. R. Caeiro Rey<sup>1</sup>, S. Dapia Robleda\*<sup>2</sup>, D. Guede Rodríguez<sup>2</sup>, M. Silva Covelo<sup>2</sup>

<sup>1</sup>Traumatology and Orthopaedic Surgery, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, <sup>2</sup>Bone Quality Research, Trabeculae, Empresa de Base Tecnológica, San Cibrao das Viñas (Ourense), Spain

**Su-P004 ACTION MECHANISMS OF DIACERHEIN ON CATABOLIC PATHWAYS OF HUMAN OSTEOARTHRITIC CHONDROCYTES**

M. Álvarez-Soria\*<sup>1</sup>, R. Largo<sup>1</sup>, J. Moreno-Rubio<sup>1</sup>, O. Sánchez-Pernaute<sup>1</sup>, S. Castañeda<sup>2</sup>, G. Herrero-Beaumont<sup>1</sup>

<sup>1</sup>Joint and Bone Research Unit, Rheumatology Department, Fundación Jiménez Díaz,

<sup>2</sup>Rheumatology Department, Hospital de La Princesa, Madrid, Spain

**Su-P005 MANDIBULAR BONE MINERAL DENSITY IN AN EXPERIMENTAL MODEL OF OSTEOPOROSIS IN RABBITS**

M. Bellido\*<sup>1</sup>, S. Castañeda<sup>2</sup>, I. Almagro<sup>3</sup>, R. Largo<sup>1</sup>, C. Gómez-Vaquero<sup>4</sup>, R. Cortez<sup>3</sup>, G. Herrero-Beaumont<sup>1</sup>

<sup>1</sup>Bone and Joint Research Unit, Fundación Jiménez Díaz, <sup>2</sup>Rheumatology Department, Hospital de La Princesa, <sup>3</sup>Oral Surgery Department of Dentistry, Fundación Jiménez Díaz, Madrid,

<sup>4</sup>Rheumatology Department, Hospital de Bellvitche, Barcelona, Spain

**Su-P006 RNA INTERFERENCE TO MODULATE COMPOSITE TISSUE ALLOGRAFT TOLERANCE BY GENE SILENCING OF JANUS KINASE 3--- PRELIMINARY RESULT IN VIVO**

K. Chang\*<sup>1</sup>, L. Chang<sup>2</sup>, S. Lin<sup>1</sup>, C. Lai<sup>3</sup>

<sup>1</sup>Plastic and Reconstructive Surgery, Kaohsiung Medical University Hospital, <sup>2</sup>Department of Microbiology, Kaohsiung Medical University, <sup>3</sup>Department of Microbiology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

**Su-P007 BONE MORPHOGENETIC PROTEIN MRNA EXPRESSION IN HUMAN PERIOSTEUM DURING FRACTURE HEALING**

C. G. Chassanidis\*<sup>1</sup>, S. Samara<sup>1</sup>, T. Koromila<sup>1</sup>, S. Varitimidis<sup>2</sup>, Z. Dailiana<sup>3</sup>, K. Malizos<sup>3</sup>, P. Kollia<sup>4</sup>

<sup>1</sup>Laboratory of Medical Genetics and Cytogenetics, School of Medicine, University of Thessaly, Institute of Biomedical Research and Technology, <sup>2</sup>Orthopaedic Surgery, University of Thessaly, <sup>3</sup>Orthopaedic Surgery, University of Thessaly, Institute of Biomedical Research and Technology, <sup>4</sup>Laboratory of Human Genetics, School of Biology, University of Athens, Athens, Institute of Biomedical Research and Technology, Larissa, Greece

**Su-P008 HIGH FREQUENCY OF OSTEOPROGENITORS IN THE PORCINE AORTIC VALVE**

J. Chen\*<sup>1</sup>, C. Yip<sup>2</sup>, E. Sone<sup>2</sup>, C. Simmons<sup>1</sup>

<sup>1</sup>Mechanical and Industrial Engineering, <sup>2</sup>Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada

**Su-P009 GENETICALLY ENGINEERED KSFRT MESENCHYMAL PROGENITORS CELLS IN COMBINATION WITH WHOLE BODY OPTICAL IMAGING PROVIDE AN EXCELLENT MODEL TO STUDY EFFECTS ON CELL FATE, BONE AND CARTILAGE FORMATION AND BIOMATERIALS**

K. E. de Rooij\*<sup>1</sup>, H. C. M. Sips<sup>1</sup>, G. van der Horst<sup>2</sup>, I. Que<sup>1</sup>, L. van der Wee-Pals<sup>1</sup>, C. W. G. Löwik<sup>1</sup>, M. Karperien<sup>3</sup>

<sup>1</sup>Endocrinology, <sup>2</sup>Urology, Leiden University Medical Center, Leiden, <sup>3</sup>Tissue Regeneration, Twente University, Enschede, Netherlands

**Su-P010 DEVELOPMENTAL CHANGES OF HISTOMORPHOMETRICAL AND PHYSICAL PROPERTIES OF RIBS IN CRITICAL POSTWEANING TIME IN PIGLETS**

P. Dobrowolski\*<sup>1</sup>, E. Sliwa<sup>2</sup>, T. Piersiak<sup>1</sup>, A. Gawron<sup>1</sup>

<sup>1</sup>Comparative Anatomy and Anthropology, Maria Curie-Skłodowska University, <sup>2</sup>Biochemistry and Animal Physiology, The Agricultural University of Lublin, Lublin, Poland

**Su-P011 NON-INVASIVE COMPARISON OF POLY LACTIDE CARBONATE IMPLANTS WITH DIFFERENT ADDITIVES ON BONE FORMATION IN OVARIECTOMISED RATS**

B. Ma<sup>1</sup>, I. H. Parkinson<sup>1</sup>, A. Badiei<sup>1</sup>, N. J. Cotton<sup>2</sup>, N. L. Fazzalari\*<sup>1</sup>

<sup>1</sup>Tissue Pathology, Institute of Medical and Veterinary Science, Adelaide, Australia, <sup>2</sup>, Smith & Nephew Inc, Mansfield, MA, United States

**Su-P012 NODULAR CELL FORMATION IN SMOOTH MUSCLE CELLS CULTURE FROM RABBIT AORTA: A SUBPOPULATION WITH INCREASED OSTEOGENIC POTENTIAL?**

F. Ferrero-Manzanal\*<sup>1</sup>, M. Suárez-Suárez<sup>1</sup>, M. del Brío-León<sup>2</sup>, A. Meana-Infiesta<sup>3</sup>, J. de Vicente-Rodríguez<sup>4</sup>, E. García-Pérez<sup>3</sup>, V. García-Díaz<sup>3</sup>, A. Murcia-Mazón<sup>1</sup>

<sup>1</sup>Orthopaedic Surgery, Hospital de Cabueñes, Gijón, <sup>2</sup>Histology, Universidad de Oviedo,

<sup>3</sup>Unidad de Ingeniería Tisular, Centro Comunitario de Sangre y Tejidos de Asturias, <sup>4</sup>Maxillo-facial Surgery, Hospital Central de Asturias, Oviedo, Spain

**Su-P013 OPTIMIZED BONE REGENERATION BASED ON SUSTAINED RELEASE FROM 3D SCAFFOLD**

Y. Fu\*<sup>1</sup>, H. Nie<sup>2</sup>, M. Ho<sup>3</sup>, C. Wang<sup>3</sup>, H. Huang<sup>2</sup>, C. Wang<sup>2</sup>

<sup>1</sup>Orthopadics, Kaohsiung Medical University, Kaohsiung, Taiwan, <sup>2</sup>Chemical and

Biomolecular Engineering, National University of Singapore, Singapore, Singapore,

<sup>3</sup>Orthopaedic Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan

**Su-P014 PHENOTYPIC COMPARISON OF INTERVERTEBRAL DISC CELLS WITH ARTICULAR AND NASAL CHONDROCYTES: TOWARDS A PHENOTYPIC SIGNATURE FOR ANNULUS FIBROSUS AND NUCLEUS PULPOSUS CELLS.**

J. Clouet<sup>1</sup>, C. Vinatier<sup>1</sup>, M. Masson<sup>1</sup>, J. Lesoeur<sup>1</sup>, Y. Cherel<sup>2</sup>, L. Guigand<sup>2</sup>, F. Rannou<sup>3</sup>, M. Corvol<sup>3</sup>, E. Bord<sup>4</sup>, G. Grimandi<sup>1</sup>, J. Guicheux\*<sup>1</sup>

<sup>1</sup>physiopathology of skeletal tissues, INSERM U791, <sup>2</sup>National veterinary school, INRA UMR 703, Nantes, <sup>3</sup>INSERM U747, University Paris Descartes, Paris, <sup>4</sup>department of neurosurgery, University hospital, Nantes, France

**Su-P015 HYPOXIA EXERTS DIFFERENTIAL EFFECTS ON THE CHONDROGENIC AND OSTEOGENIC DIFFERENTIATION OF HUMAN ADIPOSE-DERIVED MESENCHYMAL STEM CELLS**

C. Merceron<sup>1</sup>, C. Vinatier<sup>1</sup>, M. Masson<sup>1</sup>, L. Guigand<sup>2</sup>, J. Amiaud<sup>2</sup>, Y. Cherel<sup>2</sup>, M. Gatius<sup>1</sup>, P. Weiss<sup>1</sup>, J. Guicheux\*<sup>1</sup>

<sup>1</sup>physiopathology of skeletal tissues, INSERM U791, <sup>2</sup>National veterinary school, INRA UMR 703, Nantes, France

**Su-P016 CALCIUM PHOSPHATE BIOMATERIALS FOR A LOCAL-DELIVERY OF BISPHOSPHONATE**

E. Verron<sup>1</sup>, H. Roussière<sup>1</sup>, B. Bujoli<sup>2</sup>, P. Janvier<sup>2</sup>, J. Bouler<sup>1</sup>, J. Guicheux\*<sup>1</sup>

<sup>1</sup>physiopathology of skeletal tissues, INSERM U791, <sup>2</sup>Laboratoire de synthèse organique, CNRS UMR 6513, Nantes, France

**Su-P017 INFLUENCE OF MECHANICAL STIMULATION AND PERFUSION ON 3-D BMSC CULTURES**

M. Jagodzinski\*<sup>1</sup>, A. Breitbart<sup>1</sup>, C. Haasper<sup>1</sup>, M. Wehmeier<sup>2</sup>, S. Hankemeier<sup>1</sup>, C. Krettek<sup>1</sup>, E. Hesse<sup>1</sup>

<sup>1</sup>Trauma Surgery, <sup>2</sup>Clinical Chemistry, Hannover Medical School, Hanover, Germany

**Su-P018 APPLICATION OF LEAST SIGNIFICANT CHANGE (LSC) IN INTERPRETATION OF SERIAL BONE MINERAL DENSITY AND BONE SIZE MEASUREMENTS IN CHILDREN AFTER LIVER TRANSPLANTATION**

M. Jaworski<sup>1</sup>, E. Karczmarewicz\*<sup>1</sup>, J. Pawlowska<sup>2</sup>, M. Teisseyre<sup>2</sup>, H. Ismail<sup>3</sup>, E. Kryskiewicz<sup>1</sup>, H. Matusik<sup>1</sup>, M. Kobylinska<sup>1</sup>, J. Socha<sup>2</sup>, P. Pludowski<sup>1</sup>, R. S. Lorenc<sup>1</sup>

<sup>1</sup>Department of Biochemistry and Experimental Medicine, <sup>2</sup>Department of Gastroenterology, Hepatology and Immunology, <sup>3</sup>Surgery and Transplantation Clinic, The Children's Memorial Health Institute, Warsaw, Poland

**Bone development and tissue engineering**

See also: **Mo-P019 - Mo-P036**

**Tu-P037 – Tu-P053**

**Cancer and metabolic bone diseases other than osteoporosis Su-P054 – Su-P067**

**Su-P054 Abstract withdrawn**

**Su-P055 CROSS SECTIONAL STUDY OF PATIENTS WITH HYPOPHOSPHATEMIC RICKETS**

S. S. Beck-Nielsen\*<sup>1</sup>, B. Brock-Jacobsen<sup>2</sup>, K. Brixen<sup>3</sup>, K. Brusgaard<sup>4</sup>, T. K. Jensen<sup>5</sup>, J. Gram<sup>6</sup>

<sup>1</sup>Department of Paediatrics, Institute of Clinical Research, <sup>2</sup>Department of Paediatrics, <sup>3</sup>Department of Endocrinology, <sup>4</sup>Department of Clinical Genetics, Odense University Hospital, <sup>5</sup>Department of Environmental Medicine, Institute of Public Health, Odense, <sup>6</sup>Department of Endocrinology, Hospital of Southwest Denmark, Esbjerg, Denmark

**Su-P056 SUBCUTANEOUS SWELLINGS OF BOTH LEGS: AN UNUSUAL PRESENTATION OF PRIMARY HYPERPARATHYROIDISM**

J. A. Blázquez\*<sup>1</sup>, A. Gato<sup>1</sup>, I. Mora<sup>1</sup>, L. Sáez<sup>1</sup>, L. Navarro<sup>2</sup>, E. Lozano<sup>3</sup>, P. Cascales<sup>4</sup>, J. P. García<sup>5</sup>, J. Solera<sup>1</sup>

<sup>1</sup>Internal Medicine, <sup>2</sup>Clinical Chemistry, <sup>3</sup>Radiology, <sup>4</sup>Surgery, <sup>5</sup>Pathology, University Hospital, Albacete, Spain

**Su-P057 EXPRESSION OF BONE MORPHOGENETIC PROTEINS AND THEIR RECEPTORS IN NORMAL HUMAN KIDNEY AND RENAL CELL CARCINOMA**

D. Bobinac\*<sup>1</sup>, T. Celic<sup>1</sup>, D. Markic<sup>2</sup>, J. Spanjol<sup>2</sup>, A. Grskovic<sup>2</sup>, I. Maric<sup>1</sup>, Z. Fuckar<sup>2</sup>

<sup>1</sup>Department of Anatomy, Faculty of Medicine, <sup>2</sup>Department of Urology, Clinical Hospital Rijeka, Rijeka, Croatia

**Su-P058 LYMPHOCYTES AND SYNOVIAL FLUID FIBROBLASTS SUPPORT THE OSTEOCLASTOGENESIS THROUGH RANKL, TNF-ALPHA, AND IL-7 IN AN IN VITRO MODEL DERIVED FROM HUMAN PSORIATIC ARTHRITIS**

G. Brunetti\*<sup>1</sup>, F. Cantatore<sup>2</sup>, A. Oranger<sup>1</sup>, G. Mori<sup>3</sup>, L. Quarta<sup>2</sup>, A. Corrado<sup>2</sup>, M. Grano<sup>1</sup>, S. Colucci<sup>1</sup>

<sup>1</sup>Human Anatomy and Histology, University of Bari, Bari, <sup>2</sup>Clinica Reumatologica "M. Carrozzo", <sup>3</sup>Biomedical Science, University of Foggia, Foggia, Italy

**Su-P059 OSTEOGENIC POTENTIAL ALTERATION BY OSTEOBLASTS OBTAINED FROM HUMAN PERIODONTITIS PATIENTS: ROLE OF TRAIL**

G. Mori\*<sup>1</sup>, G. Brunetti<sup>2</sup>, S. Colucci<sup>2</sup>, F. Ciccolella<sup>3</sup>, P. Pignataro<sup>2</sup>, A. Oranger<sup>2</sup>, C. Mori<sup>4</sup>, F. Grassi<sup>3</sup>, M. Grano<sup>2</sup>

<sup>1</sup>Biomedical Science, University of Foggia, Foggia, <sup>2</sup>Human Anatomy and Histology, <sup>3</sup>Oral Science, Section of Oral Surgery, <sup>4</sup>Orthopaedic Surgery, University of Bari, Bari, Italy

**Su-P060 Abstract withdrawn**

**Su-P061 BISPHOSPHONATE INDUCED-METAPHYSEAL SCLEROTIC BANDS IN THE FEMUR INVOLVED BY FIBROUS DYSPLASIA. A COMPARATIVE STUDY BETWEEN AFFECTED AND UNAFFECTED TISSUE.**

A. Corsi\*<sup>1</sup>, F. De Maio<sup>2</sup>, A. Stracuzzi<sup>1</sup>, A. Funari<sup>1</sup>, E. Ippolito<sup>2</sup>, M. Riminucci<sup>1</sup>, P. Bianco<sup>1</sup>

<sup>1</sup>Experimental Medicine, University La Sapienza, <sup>2</sup>Orthopedic Surgery, University Tor Vergata, Rome, Italy

**Su-P062 IMMUNOASSAYING OF BONE MORPHOGENETIC PROTEIN-9 AND ITS RECEPTORS IN LIVER AND PANCREAS OF DIABETIC WISTAR RATS**

O. Cvijanovic\*<sup>1</sup>, T. Celic<sup>1</sup>, S. Peternel<sup>2</sup>, I. Maric<sup>1</sup>, Z. Crncevic - Orlic<sup>3</sup>, T. Turk<sup>3</sup>, D. Bobinac<sup>1</sup>

<sup>1</sup>Department of Anatomy, <sup>2</sup>Department of Pharmacology, Medical Faculty University in Rijeka,

<sup>3</sup>Department of Internal Medicine, Clinical Hospital Rijeka, Rijeka, Croatia

**Su-P063 EXPRESSION OF BONE MORPHOGENETIC PROTEIN-9 IN ADULT HUMAN LIVER**

O. Cvijanovic\*<sup>1</sup>, T. Celic<sup>1</sup>, S. Peternel<sup>2</sup>, S. Stifter<sup>3</sup>, Z. Crncevic - Orlic<sup>4</sup>, S. Zoricic Cvek<sup>1</sup>, D. Bobinac<sup>1</sup>

<sup>1</sup>Department of Anatomy, <sup>2</sup>Department of Pharmacology, <sup>3</sup>Department of Pathology, Medical Faculty University in Rijeka, <sup>4</sup>Department of Internal Medicine, Clinical Hospital Rijeka, Rijeka, Croatia

**Su-P064 FOLLOW-UP OF ARTERIAL CALCIFICATIONS IN RATS WITH CHRONIC RENAL FAILURE: A QUANTITATIVE IN VIVO AND IN VITRO MICROTOMOGRAPHY ANALYSIS**

A. Postnov<sup>1</sup>, V. Persy<sup>2</sup>, E. Neven<sup>2</sup>, P. D'Haese<sup>2</sup>, N. De Clerck\*<sup>3</sup>

<sup>1</sup>Department of Physics, <sup>2</sup>Laboratory of Pathophysiology, <sup>3</sup>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

**Su-P065 EFFECT OF STOPPING ANASTROZOLE ON BONE MINERAL DENSITY: SEVEN-YEAR RESULTS FROM THE ATAC TRIAL**

R. Eastell\*<sup>1</sup>, J. E. Adams<sup>2</sup>, G. Clack<sup>3</sup>, A. Howell<sup>4</sup>, R. A. Hannon<sup>1</sup>, J. Cuzick<sup>5</sup>, J. R. Mackey<sup>6</sup>, M. Beckmann<sup>7</sup>, R. Coleman<sup>8</sup>

<sup>1</sup>Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, <sup>2</sup>Diagnostic Radiology, Imaging Science and Biomedical Engineering, The University of Manchester, Manchester,

<sup>3</sup>Research and Development, AstraZeneca, Macclesfield, <sup>4</sup>Manchester Breast Centre, Christie

Hospital NHS Trust, Manchester, <sup>5</sup>Department of Epidemiology Mathematics and Statistics,

Wolfson Institute of Preventive Medicine, London, United Kingdom, <sup>6</sup>Division of Medical

Oncology, Cross Cancer Institute, Edmonton, Canada, <sup>7</sup>Frauenklinik, Universitat Erlangen-

Nurnberg, Erlangen, Germany, <sup>8</sup>Cancer Research Centre, Weston Park Hospital, Sheffield,

United Kingdom

**Su-P066 COLLAGEN AND PROTEOGLYCAN PERTURBATIONS IN  
CARTILAGE OF PATIENTS WITH MORQUIO A DISEASE**

R. Bank<sup>1</sup>, J. Groener<sup>2</sup>, K. Hoeben<sup>3</sup>, V. Everts\*<sup>4</sup>

<sup>1</sup>Tissue Repair, TNO Quality of Life, Leiden, <sup>2</sup>Biochemistry, <sup>3</sup>Cell Biology, AMC, <sup>4</sup>Oral Cell Biology, Academic Center for dentistry Amsterdam, Universiteit van Amsterdam and Vrije Universiteit, Amsterdam, Netherlands

**Su-P067 INTRAVENOUS ZOLEDRONIC ACID (ZOL) COMPARED TO IV  
PAMIDRONATE (PAM) IN CHILDREN WITH SEVERE OSTEOGENESIS  
IMPERFECTA (OI)**

F. H. Glorieux\*<sup>1</sup>, N. Bishop<sup>2</sup>, M. Bober<sup>3</sup>, C. E. Brain<sup>4</sup>, J. Devogelaer<sup>5</sup>, G. Fekete<sup>6</sup>, V. Forin<sup>7</sup>, R. J. Hopkin<sup>8</sup>, I. Kaitila<sup>9</sup>, B. Lee<sup>10</sup>, R. Lorenc<sup>11</sup>, J. D. Mahan<sup>12</sup>, J. A. McCallister<sup>13</sup>, J. M. Pettifor<sup>14</sup>, H. Plotkin<sup>15</sup>, F. Rauch<sup>1</sup>, I. B. Salusky<sup>16</sup>, N. Shaw<sup>17</sup>, L. Showalter<sup>18</sup>, J. W. Steelman<sup>19</sup>, R. Steiner<sup>20</sup>, M. Tan<sup>21</sup>, W. Zhou<sup>21</sup>, C. Bucci-Rechtweg<sup>21</sup>

<sup>1</sup>Shriners Hospital for Children, McGill University, Montreal, Canada, <sup>2</sup>Sheffield Children's Hospital, Sheffield, United Kingdom, <sup>3</sup>Alfred I. DuPont Hospital for Children, Wilmington, DE, United States, <sup>4</sup>Great Ormond Street Hospital for Children, London, United Kingdom, <sup>5</sup>Cliniques Universitaires St. Luc, Brussels, Belgium, <sup>6</sup>Semmelweis Egyetem, Budapest, Hungary, <sup>7</sup>Hopital Trousseau, Paris, France, <sup>8</sup>Children's Hospital Medical Center, Cincinnati, OH, United States, <sup>9</sup>Helsingin Yliopisto Haartman Instituutti, Helsinki, Finland, <sup>10</sup>Texas Children's Hospital, Houston, TX, United States, <sup>11</sup>Zaklad Biochemii I Medycyny Doswiadczalnej, Warsaw, Poland, <sup>12</sup>Children's Hospital, Columbus, OH, <sup>13</sup>St. Jude Children's Research Hospital, Peoria, IL, United States, <sup>14</sup>Chris Hani Bara Hospital, Soweto, South Africa, <sup>15</sup>Children's Hospital, Nebraska Medical Center, Omaha, NE, <sup>16</sup>UCLA Medical Center, Los Angeles, CA, United States, <sup>17</sup>Birmingham Children's Hospital, Birmingham, United Kingdom, <sup>18</sup>Intermountain Orthopedics, Boise, ID, <sup>19</sup>Vanderbilt University Medical Center, Nashville, TN, <sup>20</sup>Vanderbilt University Medical Center, Oregon Health Sciences University, <sup>21</sup>Novartis Pharmaceuticals Corp, East Hanover, NJ, United States

**Cancer and metabolic bone diseases other than osteoporosis**

See also: **Mo-P068 - Mo-P080**

**Tu-P081 – Tu-P093**

**Cell biology: osteoblasts, osteocytes and bone formation**

**Su-P094 – Su-P120**

**Su-P094 INTRATRABECULAR TUNNELING INCREASES TRABECULAR  
NUMBER THROUGHOUT THE SKELETON OF OVARIECTOMIZED RHESUS  
MONKEYS TREATED WITH PARATHYROID HORMONE (1-84)**

M. A. Miller\*<sup>1</sup>, S. P. Bare<sup>2</sup>, R. R. Recker<sup>2</sup>, S. Y. Smith<sup>3</sup>, J. Fox<sup>1</sup>

<sup>1</sup>International Medical Scientific Strategy and Medical Marketing, Nycomed, Roskilde, Denmark, <sup>2</sup>Osteoporosis Research Center, Creighton University, Omaha, NE, United States, <sup>3</sup>Charles River Laboratories, Preclinical Services, Montréal, Quebec, Canada

**Su-P095 IDIOPATHIC MULTIPLE LUMBAR INTEVERTEBRAL DISC  
CALCIFICATIONS**

S. Al-Naser\*<sup>1</sup>, T. Nasser<sup>2</sup>, O. Al-Omoush<sup>1</sup>

<sup>1</sup>Orthopaedics, Morriston Hospital, Swansea, <sup>2</sup>General Surgery, Tameside General Hospital, Manchester, United Kingdom

**Su-P096 PROTEIN EXPRESSION ANALYSIS OF A HUMAN OSTEOBLAST DIFFERENTIATION MODEL**

R. Alves\*<sup>1</sup>, M. Eijken<sup>1</sup>, S. Swagemakers<sup>2</sup>, P. C. Burgers<sup>3</sup>, M. Titulaer<sup>3</sup>, R. Lamers<sup>3</sup>, T. M. Luider<sup>3</sup>, J. P. T. M. van Leeuwen<sup>1</sup>

<sup>1</sup>Department of Internal Medicine, <sup>2</sup>Department of Bioinformatics, <sup>3</sup>Department of Neurology, ErasmusMC, Rotterdam, Netherlands

**Su-P097 OSTEOBLAST FIBRONECTIN AFFECTS THEIR BEHAVIOR IN VIVO**

A. Bentmann\*<sup>1</sup>, N. Kawelke<sup>1</sup>, D. Moss<sup>2</sup>, I. A. Nakchbandi<sup>1</sup>

<sup>1</sup>Max-Planck Institute for Biochemistry, Martinsried, Institute for Immunology, University of Heidelberg, Heidelberg, <sup>2</sup>Research Center Karlsruhe, ANKA Facility, Karlsruhe, Germany

**Su-P098 CIRCULATING PLASMA FIBRONECTIN IS NEEDED FOR A NORMAL BONE DENSITY**

A. Bentmann\*<sup>1</sup>, N. Kawelke<sup>1</sup>, J. Gasser<sup>2</sup>, I. A. Nakchbandi<sup>1</sup>

<sup>1</sup>Max-Planck Institute for Biochemistry, Martinsried, Institute for Immunology, University of Heidelberg, Heidelberg, Germany, <sup>2</sup>Novartis Institutes for Biomedical Research, WKL-125.901, Basel, Switzerland

**Su-P099 STRONTIUM RANELATE-INDUCED INCREASES IN OPG ARE MEDIATED BY THE OSTEOBLASTIC CALCIUM-SENSING RECEPTOR**

T. C. Brennan\*<sup>1</sup>, M. S. Rybchyn<sup>1</sup>, A. D. Conigrave<sup>2</sup>, R. S. Mason<sup>1</sup>

<sup>1</sup>School of Medical Sciences and Bosch Institute, <sup>2</sup>School of Molecular and Microbial Biosciences, University of Sydney, Sydney, Australia

**Su-P100 THE OSTEOPOROTIC EFFECTS OF ROSIGLITAZONE ARE NOT CAUSED BY A DIRECT NEGATIVE ACTION ON HUMAN OSTEOBLAST DIFFERENTIATION**

C. Bruedigam\*<sup>1</sup>, M. Eijken<sup>1</sup>, M. Schreuders-Koedam<sup>1</sup>, J. P. T. M. van Leeuwen<sup>1</sup>

<sup>1</sup>Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands

**Su-P101 SEVERE OSTEOPENIA IN PERK-KNOCKOUT MICE IS DUE TO IMPAIRED OSTEOBLAST DIFFERENTIATION AND PROLIFERATION, AND ER RETENTION OF PROCOLLAGEN-I**

J. Wei<sup>1</sup>, X. Sheng<sup>1</sup>, J. Morrow<sup>1</sup>, B. McGrath<sup>1</sup>, D. R. Cavener\*<sup>1</sup>

<sup>1</sup>Biology, Penn State University, University Park, United States

**Su-P102 PRIMARY MURINE OSTEOBLAST CULTURES CONTAIN MACROPHAGES THAT ENHANCE OSTEOBLAST MINERALISATION**

M. K. Chang\*<sup>1</sup>, A. R. Pettit<sup>1</sup>, K. Schroder<sup>1</sup>, V. M. Ripoll<sup>1</sup>, K. A. Alexander<sup>1</sup>, D. A. Hume<sup>2</sup>, L. Raggatt<sup>1</sup>

<sup>1</sup>Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia, <sup>2</sup>The Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom

**Su-P103 INVOLVEMENT OF GAS7 ALONG THE ERK 1/2 MAP KINASE AND SOX9 PATHWAY IN CHONDROGENESIS OF HUMAN MARROW DERIVED MESENCHYMAL STEM CELLS**

Y. Chang\*<sup>1</sup>

<sup>1</sup>Orthopaedic, Chang Gung Memorial Hospital, Kweishan, Taiwan

**Su-P104 (-)-EPIGALLOCATECHIN-3-GALLATE (EGCG) INCREASES OPG/RANKL EXPRESSION IN OSTEOCLAST FEEDER CELL, ST2**

P. Huang\*<sup>1</sup>, C. Chen<sup>1</sup>, L. Kang<sup>2</sup>, S. Hung<sup>1</sup>, G. Wang<sup>1</sup>, J. Chang<sup>1</sup>

<sup>1</sup>Department of Orthopedics, Kaohsiung Medical University, Kaohsiung, <sup>2</sup>Department of Obstetrics and Gynecology, National Cheng Kung University, Tainan, Taiwan

**Su-P105 EFFECTS OF HL39 ON BONE REMODELLING: A ROLE FOR THE PROLIFERATION AND DIFFERENTIATION**

H. Yoon\*<sup>1</sup>, S. Yun<sup>1</sup>, S. Yi<sup>1</sup>, S. Jeong<sup>2</sup>, N. Song<sup>3</sup>, J. Ryu<sup>3</sup>, Y. Chung<sup>1</sup>

<sup>1</sup>Endocrinology and Metabolism, <sup>2</sup>Medical Genetics, Ajou University School of Medicine, Suwon, <sup>3</sup>HL Genomics, HL Genomics, Yongin, South Korea

**Su-P106 EFFECTS OF ARACHIDONIC ACID AND DOCOSAHEXAENOIC ACID ON DIFFERENTIATION OF AND MINERALIZATION BY MC3T3-E1 OSTEOBLAST-LIKE CELLS**

M. Coetzee\*<sup>1</sup>, M. Haag<sup>1</sup>, M. C. Kruger<sup>2</sup>

<sup>1</sup>Department of Physiology, University of Pretoria, Pretoria, South Africa, <sup>2</sup>Institute of Food, Nutrition and Human Health, Massey University, Palmerston North, New Zealand

**Su-P107 EFFECTS OF CYCLOSPORINE, TACROLIMUS AND RAPAMYCIN ON OPG, RANKL AND IL6 EXPRESSION, AND CELL SURVIVAL IN HUMAN OSTEOBLASTS**

M. Montero\*<sup>1</sup>, R. Largo<sup>1</sup>, M. Rubert<sup>1</sup>, C. De la Piedra<sup>1</sup>

<sup>1</sup>Osteoarticular Pathology Laboratory, Fundacion Jimenez Diaz, Madrid, Spain

**Su-P108 CATABOLIC FUNCTIONS OF ENDOSTEAL BONE LINING CELLS ANALYZED BY LASER-ASSISTED MICRODISSECTION AND RT-PCR.**

C. Dierkes\*<sup>1</sup>, M. Kreisel<sup>1</sup>, J. Wolff<sup>1</sup>, L. Fink<sup>1</sup>, A. Schulz<sup>1</sup>

<sup>1</sup>Institute of Pathology, Justus-Liebig University, Giessen, Germany

**Su-P109 THE INFLUENCE OF CASEINPHOSHOPEPTIDES ON INTRACELLULAR CALCIUM CHANGES IN PRIMARY HUMAN OSTEOBLASTS: A NUTRIENT DEPENDENT MODULATION OF BONE CELL METABOLISM**

B. M. Donida\*<sup>1</sup>, E. Mrak<sup>2</sup>, C. Gravaghi<sup>1</sup>, I. Villa<sup>2</sup>, S. Cosentino<sup>1</sup>, A. Rubinacci<sup>2</sup>, G. Tettamanti<sup>1</sup>, A. Ferraretto<sup>1</sup>

<sup>1</sup>Department of Medical Chemistry, Biochemistry and Biotechnology, University of Milan,

<sup>2</sup>Bone Metabolic Unit, San Raffaele Hospital, Segrate, Italy

**Su-P110 PERIOSTIN IS A PARATHYROID HORMONE REGULATED OSTEOBLAST DERIVED BONE MATRIX PROTEIN**

D. Fortunati\*<sup>1</sup>, Å. K. Fjeldheim<sup>1</sup>, S. Reppe<sup>1</sup>, M. Nielsen<sup>1</sup>, P. I. Høvring<sup>1</sup>, V. T. Gautvik<sup>1</sup>, K. M. Gautvik<sup>2</sup>

<sup>1</sup>Dept. of Biochemistry, Institute of Basic Medical Sciences, University of Oslo, Norway, <sup>2</sup>Dept. of Biochemistry, Institute of Basic Medical Sciences, University of Oslo and Ullevaal University Hospital, Oslo, Norway

**Su-P111 EXPRESSION OF TWO-PORE DOMAIN POTASSIUM (K2P) CHANNELS IN OSTEOBLASTIC CELLS IS RELATED TO DIFFERENTIATION**

A. W. Gallagher\*<sup>1</sup>, A. P. Bond<sup>1</sup>, J. A. Gallagher<sup>1</sup>, J. M. Quayle<sup>1</sup>

<sup>1</sup>*Human Anatomy and Cell Biology, University of Liverpool, Liverpool, United Kingdom*

**Su-P112 REGULATION OF PROTEASE-ACTIVATED RECEPTOR-2 EXPRESSION IN MOUSE PRIMARY OSTEOBLASTS BY HORMONES, GROWTH FACTORS AND CYTOKINES**

S. R. Georgy\*<sup>1</sup>, C. N. Pagel<sup>1</sup>, E. J. Mackie<sup>1</sup>

<sup>1</sup>*School of Veterinary Science, University of Melbourne, Melbourne, Australia*

**Su-P113 BMP-4 IS DOWN-REGULATED TOGETHER WITH RUNX2 IN THE PERIPHERAL BLOOD OF PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS BUT NOT ANKYLOSING SPONDYLITIS**

D. Grcevic\*<sup>1</sup>, N. Kovacic<sup>2</sup>, Z. Jajic<sup>3</sup>, S. Ivcevic<sup>1</sup>, F. Grubisic<sup>3</sup>, A. Marusic<sup>2</sup>

<sup>1</sup>*Department of Physiology and Immunology, <sup>2</sup>Department of Anatomy, Zagreb University School of Medicine, <sup>3</sup>University Department for Rheumatology, Physical Medicine and Rehabilitation, Sisters of Mercy University Hospital, Zagreb, Croatia*

**Su-P114 A 90KDA BONE-SPECIFIC ANTIGEN LOCALISED TO THE GOLGI APPARATUS OF OSTEOBLASTS**

V. J. Green\*<sup>1</sup>, P. W. Wilson<sup>1</sup>, A. A. Walsh<sup>1</sup>, J. A. Gallagher<sup>1</sup>

<sup>1</sup>*Human Anatomy and Cell Biology, University of Liverpool, Liverpool, United Kingdom*

**Su-P115 ERK1/2 AND FRA-1 MEDIATE PHOSPHATE-DEPENDENT STIMULATION OF MATRIX GLA PROTEIN EXPRESSION IN OSTEOBLASTS**

M. Julien<sup>1</sup>, S. Khoshniat\*<sup>1</sup>, A. Lacreusette<sup>2</sup>, M. Masson<sup>1</sup>, A. Bozec<sup>3</sup>, E. Wagner<sup>3</sup>, P. Weiss<sup>1</sup>, D. Magne<sup>4</sup>, J. Guicheux<sup>1</sup>

<sup>1</sup>*Physiopathology of skeletal tissues, INSERM U791, <sup>2</sup>Cytokines et récepteurs, INSERM U 601, Nantes, France, <sup>3</sup>Research institute of molecular pathology, University of Vienna, Vienna, Austria, <sup>4</sup>LR2B, INSERM ERI 002, Boulogne sur mer, France*

**Su-P116 CALCIUM IS REQUIRED FOR PHOSPHATE-DEPENDENT STIMULATION OF MGP AND OPN EXPRESSION IN OSTEOBLASTS**

S. Khoshniat\*<sup>1</sup>, M. Julien<sup>1</sup>, L. Beck<sup>2</sup>, M. Petit<sup>3</sup>, T. Rouillon<sup>1</sup>, M. Masson<sup>1</sup>, M. Gatius<sup>1</sup>, P. Weiss<sup>1</sup>, J. Guicheux<sup>1</sup>

<sup>1</sup>*Physiopathology of skeletal tissues, INSERM U791, Nantes, <sup>2</sup>Centre de recherche croissance et signalisation, INSERM U 845, Paris, <sup>3</sup>Laboratoire de synthèse organique, CNRS UMR 6513, Nantes, France*

**Su-P117 GROWTH HORMONE STIMULATES PROLIFERATION AND DIFFERENTIATION OF M2H4 ODONTOBLASTIC CELL LINE**

S. Lopez-Cazaux<sup>1</sup>, T. Cordonnier<sup>1</sup>, M. Julien<sup>1</sup>, M. Masson<sup>1</sup>, M. Gatius<sup>1</sup>, S. Khoshniat<sup>1</sup>, P. Weiss<sup>1</sup>, j. guicheux\*<sup>1</sup>, B. Alliot-Licht<sup>1</sup>

<sup>1</sup>*physiopathology of skeletal tissues, INSERM U791, Nantes, France*

**Su-P118 INDEPENDENT OF THEIR RESORPTIVE ACTIVITY, OSTEOCLASTS SECRETE AN ACTIVITY INDUCING BONE FORMATION AND CANONICAL WNT SIGNALLING IN OSTEOBLASTIC CELLS**

K. Henriksen\*<sup>1</sup>, A. V. Neutzsky-Wulff<sup>1</sup>, K. D. Hausler<sup>2</sup>, M. Ciccomancini<sup>2</sup>, C. Christiansen<sup>1</sup>, M. Gillespie<sup>2</sup>, T. J. Martin<sup>2</sup>, M. A. Karsdal<sup>1</sup>

<sup>1</sup>*Pharmacology, Nordic Bioscience, Herlev, Denmark, <sup>2</sup>-, St. Vincent's Institute of Medical*

Research, Melbourne, Australia

**Su-P119 LOCALIZATION OF RUNX2, OSTERIX AND OSTEOPONTIN IN CEMENTOGENESIS IN RAT MOLARS**

A. Hirata\*<sup>1</sup>, T. Ueno<sup>2</sup>, T. Kagawa<sup>2</sup>, T. Matsumura<sup>2</sup>, T. Yamada<sup>2</sup>, K. Mishima<sup>2</sup>, T. Sugahara<sup>2</sup>, H. Nakamura<sup>3</sup>

<sup>1</sup>Department of Oral Morphology, <sup>2</sup>Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama, <sup>3</sup>Department of Oral Histology, Matsumoto Dental University, Shiojiri, Japan

**Su-P120 PIOGLITAZONE AND DEXAMETHASONE INDUCE ADIPOGENESIS IN DI BONE MARROW STROMAL CELL LINE, BUT NOT THROUGH THE PPAR $\gamma$  PATHWAY**

S. Hung\*<sup>1</sup>, C. Chen<sup>2</sup>, H. Huang<sup>2</sup>, C. Wang<sup>3</sup>, D. Chao<sup>4</sup>, G. Wang<sup>2</sup>

<sup>1</sup>Center of Basic Medical Science Education, Fooyin University, 151, Chihhsueh Rd., Ta-liao, Kaohsiung, <sup>2</sup>Orthopedic Surgery, <sup>3</sup>Biotechnology, Kaohsiung Medical University, <sup>4</sup>Biological Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan

**Cell biology: osteoblasts, osteocytes and bone formation**

**See also: Mo-P121 - Mo-P147**

**Tu-P148 - Tu-P174**

**Cell biology: osteoclasts and bone resorption Su-P175 - Su-P185**

**Su-P175 IMPAIRED BONE RESORPTION ASSOCIATED WITH PYCNODYSTOSIS**

M. Ainola\*<sup>1</sup>, Y. T. Kontinen<sup>2</sup>

<sup>1</sup>Clinical Medicine, University of Helsinki, <sup>2</sup>Clinical Medicine, Helsinki University Central Hospital, Helsinki, Finland

**Su-P176 EXPRESSION OF CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR (CFTR) IN HUMAN BONE CELLS**

C. A. Beeton\*<sup>1</sup>, A. M. Condliffe<sup>1</sup>, E. F. Shead<sup>1</sup>, C. S. Haworth<sup>2</sup>, J. E. Compston<sup>1</sup>

<sup>1</sup>Department of Medicine, University of Cambridge, <sup>2</sup>Adult CF Centre, Papworth NHS Foundation Trust, Cambridge, United Kingdom

**Su-P177 DEXAMETHASONE REDUCES OSTEOCLAST FORMATION BY AFFECTING ADHESION BETWEEN OSTEOCLAST PRECURSORS AND OSTEOBLASTS**

V. Bloemen\*<sup>1</sup>, T. Schoenmaker<sup>2</sup>, T. J. de Vries<sup>2</sup>, V. Everts<sup>1</sup>

<sup>1</sup>Department of Oral Cell Biology, <sup>2</sup>Departments of Oral Cell Biology and Periodontology, Academic Centre of Dentistry Amsterdam, Amsterdam, Netherlands

**Su-P178 OSTEOCLAST SIZE AND SURVIVAL IS CONTROLLED BY FRA-2 THROUGH LIF/LIF-RECEPTOR SIGNALING AND HYPOXIA**

A. Bozec\*<sup>1</sup>, L. Bakiri<sup>1</sup>, A. Hoebertz<sup>1</sup>, R. Eferl<sup>1</sup>, A. F. Schilling<sup>2</sup>, V. Komnenovic<sup>1</sup>, H. Scheuch<sup>1</sup>, M. Priemel<sup>2</sup>, C. L. Stewart<sup>3</sup>, M. Amling<sup>2</sup>, E. F. Wagner<sup>1</sup>

<sup>1</sup>Research Institute of Molecular Pathology, I.M.P., Vienna, Austria, <sup>2</sup>Department of Trauma,

*Hand, and, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, <sup>3</sup>Cancer and Developmental Biology Laboratory, National Cancer Institute, Frederick, MD 21702, USA, United States*

**Su-P179 EXTRA RENAL HYDROXYLATION IN HUMAN BONE CELLS**

N. Bravenboer\*<sup>1</sup>, E. E. E. Ahmad<sup>2</sup>, H. W. van Essen<sup>2</sup>, P. Lips<sup>2</sup>

*<sup>1</sup>Endocrinology and Clinical Chemistry, <sup>2</sup>Endocrinology, Free University Medical Center, Amsterdam, Netherlands*

**Su-P180 GREEN TEA CATECHIN (-)-EPIGALLOCATECHIN-3-GALLATE INHIBITS OSTEOCLASTIC DIFFERENTIATION VIA SUPPRESSION OF NF-KB**

C. Chen\*<sup>1</sup>, R. Lin<sup>2</sup>, M. Ho<sup>3</sup>, Y. Wang<sup>2</sup>, I. Chen<sup>4</sup>, G. Wang<sup>2</sup>, L. Kang<sup>5</sup>

*<sup>1</sup>Department of Orthopedics, <sup>2</sup>Orthopedic Research Center, <sup>3</sup>Departments of Physiology, <sup>4</sup>Graduate Institute of Pharmaceutical Sciences, Kaohsiung Medical University, Kaohsiung, <sup>5</sup>Department of Obstetrics and Gynecology, National Cheng Kung University, Tainan, Taiwan*

**Su-P181 INHIBITION OF RAB GERANYLGERANYL TRANSFERASE AND RAB PRENYLATION BY PHOSPHONOCARBOXYLATE DRUGS**

F. P. Coxon\*<sup>1</sup>, C. A. Stewart<sup>1</sup>, R. Tavares<sup>2</sup>, R. Baron<sup>2</sup>, A. Taylor<sup>1</sup>, M. S. Marma<sup>3</sup>, K. M.

*Blazewska<sup>3</sup>, B. A. Kashemirov<sup>3</sup>, F. H. Ebetino<sup>4</sup>, M. C. Seabra<sup>2</sup>, M. J. Rogers<sup>1</sup>, C. E. McKenna<sup>3</sup>  
<sup>1</sup>Bone Research Programme, University of Aberdeen, Aberdeen, <sup>2</sup>Cell and Molecular Biology, Imperial College, London, United Kingdom, <sup>3</sup>Department of Chemistry, University of Southern California, Los Angeles, <sup>4</sup>Procter & Gamble Pharmaceuticals, Mason, United States*

**Su-P182 FLUORESCENTLY LABELED RISEDRONATE AND RELATED ANALOGS: DESIGN AND EVALUATION AS IMAGING PROBES**

F. P. Coxon\*<sup>1</sup>, J. L. Bala<sup>2</sup>, B. A. Kashemirov<sup>2</sup>, A. J. Roelofs<sup>1</sup>, M. Lundy<sup>3</sup>, X. Chen<sup>2</sup>, Z. Xia<sup>4</sup>, J. E. Dunford<sup>4</sup>, R. G. Russell<sup>4</sup>, M. J. Rogers<sup>1</sup>, C. E. McKenna<sup>2</sup>, F. Ebetino<sup>3</sup>

*<sup>1</sup>Bone Research Programme, University of Aberdeen, Aberdeen, United Kingdom, <sup>2</sup>Department of Chemistry, University of Southern California, Los Angeles, <sup>3</sup>Procter & Gamble Pharmaceuticals, Mason, United States, <sup>4</sup>Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford, United Kingdom*

**Su-P183 MUTATIONS ASSOCIATED WITH PAGETIC DISEASES CAUSE LACK OF SIGNAL PEPTIDE CLEAVAGE OF RANK, AND ACCUMULATION WITHIN ORGANISED SMOOTH ENDOPLASMIC RETICULUM WHEN OVEREXPRESSED.**

D. J. Mellis\*<sup>1</sup>, K. I. J. Shennan<sup>2</sup>, A. Duthie<sup>1</sup>, J. Greenhorn<sup>1</sup>, M. Helfrich<sup>1</sup>, M. J. Rogers<sup>1</sup>, J. C. Crockett<sup>1</sup>

*<sup>1</sup>Bone and Musculoskeletal Research Programme, <sup>2</sup>Cell and Developmental Research Programme, University of Aberdeen, Aberdeen, United Kingdom*

**Su-P184 REDUCED BONE DENSITY IN XLA PATIENTS, AN EFFECT OF B-CELL DEFICIENCY ON OSTEOCLAST DIFFERENTIATION AND OSTEOLYTIC ACTIVITY**

L. Danks, Lynett\*<sup>1</sup>, S. Workman<sup>2</sup>, D. A. Webster<sup>2</sup>, B. M. Foxwell<sup>1</sup>, N. J. Horwood<sup>1</sup>

*<sup>1</sup>Kennedy Institute of Rheumatology, Imperial College London, <sup>2</sup>Department of Immunology, Royal Free and University College Medical School, London, United Kingdom*

**Su-P185 CHARACTERIZATION OF THE ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)-DELTA IN OSTEOCLAST BIOLOGY**

J. M. Fidalgo\*<sup>1</sup>, B. Fletcher<sup>1</sup>, G. Muscat<sup>1</sup>, D. Ovchinnikov<sup>1</sup>, A. I. Cassady<sup>1</sup>

<sup>1</sup>*Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia*

**Cell biology: osteoclasts and bone resorption**

See also: **Mo-P186 - Mo-P196**

**Tu-P197 - Tu-P206**

**Genetics Su-P207 – Su-P217**

**Su-P207 TRANSCRIPTIONAL PROFILE OF IMMUN SYSTEM-RELATED GENES IN POSTMENOPAUSAL OSTEOPOROTIC VERSUS NON-OSTEOPOROTIC HUMAN BONE TISSUE**

B. Balla\*<sup>1</sup>, J. P. Kósa<sup>1</sup>, J. Kiss<sup>2</sup>, J. Podani<sup>3</sup>, Á. Lazáry<sup>1</sup>, K. Bácsi<sup>1</sup>, Z. Nagy<sup>1</sup>, G. Speer<sup>1</sup>, I. Takács<sup>1</sup>, P. Lakatos<sup>1</sup>

<sup>1</sup>*1st Department of Internal Medicine, <sup>2</sup>Department of Orthopaedics, Semmelweis University, <sup>3</sup>Department of Plant Taxonomy and Ecology, Eötvös Loránd University, Budapest, Hungary*

**Su-P208 CALCIUM-SENSING RECEPTOR GENE “A986S” POLYMORPHISM: GENOTYPE FREQUENCIES AND RELATION TO BONE MINERAL DENSITY IN A SPANISH EARLY POSTMENOPAUSAL WOMEN POPULATION**

J. A. Blázquez\*<sup>1</sup>, L. Navarro<sup>2</sup>, C. Andrés<sup>2</sup>, J. Ontañón<sup>2</sup>, J. Del Pino<sup>3</sup>

<sup>1</sup>*Internal Medicine, <sup>2</sup>Clinical Chemistry, University Hospital, Albacete, <sup>3</sup>Rheumatology, University Hospital, Salamanca, Spain*

**Su-P209 EP2/EP4 MEDIATED PGE2 SIGNALLING INCREASES GENE EXPRESSION AND THE SYNTHESIS OF OSTEOPROTEGERIN (OPG) AND RECEPTOR ACTIVATOR OF NF-KAPPA B LIGAND (RANKL) IN HUMAN OSTEOARTHRITIC CHONDROCYTES**

J. Moreno-Rubio\*<sup>1</sup>, G. Herrero-Beaumont<sup>1</sup>, L. Tardío<sup>1</sup>, S. Castañeda<sup>2</sup>, R. Largo<sup>1</sup>

<sup>1</sup>*Joint and Bone Research Unit, Rheumatology Department, Fundación Jiménez Díaz, <sup>2</sup>Rheumatology Department, Hospital de La Princesa, Madrid, Spain*

**Su-P210 NSAID TREATMENT DECREASES COX-2 AND MPGES-1 PRODUCTION BY OSTEOARTHRITIC CHONDROCYTES OF PATIENTS WITH SEVERE KNEE OSTEOARTHRITIS**

R. Largo\*<sup>1</sup>, M. Álvarez-Soria<sup>1</sup>, J. Moreno-Rubio<sup>1</sup>, E. Calvo<sup>1</sup>, S. Castañeda<sup>2</sup>, G. Herrero-Beaumont<sup>1</sup>

<sup>1</sup>*Joint and Bone Research Unit, Rheumatology Department, Fundación Jiménez Díaz, <sup>2</sup>Rheumatology Department, Hospital de La Princesa, Madrid, Spain*

**Su-P211 CHARACTERISATION OF A NEW MOUSE LINE DISPLAYING OSTEOARTHRITIS, CHONDRODYSPLASIA AND ECTOPIC BONE FORMATION**

C. M. Cohrs\*<sup>1</sup>, T. S. Lisse<sup>2</sup>, W. Hans<sup>1</sup>, H. Fuchs<sup>1</sup>, G. K. H. Przemeck<sup>1</sup>, M. Hrabé de Angelis<sup>1</sup>

<sup>1</sup>*Institute of Experimental Genetics, Helmholtz Center Munich, German Research Center for Environmental Health GmbH, Neuherberg, Germany, <sup>2</sup>National Institute of Child Health &*

*Human Development, NIH, Maryland, United States*

**Su-P212 TRANSCRIPTIONAL REGULATION OF THE XENOPUS LAEVIS MATRIX GLA PROTEIN GENE**

N. Conceição\*<sup>1</sup>, C. Fazenda<sup>1</sup>, B. Simões<sup>1</sup>, L. Cancela<sup>1</sup>

<sup>1</sup>*CCMar, University of Algarve, Faro, Portugal*

**Su-P213 PROGNOSTIC AND THERAPEUTIC VALUE OF AUTOSOMAL RECESSIVE OSTEOPETROSIS GENETIC DISSECTION**

M. M. Guerrini\*<sup>1</sup>, C. Sobacchi<sup>1</sup>, A. Pangrazio<sup>1</sup>, E. Caldana<sup>1</sup>, M. H. Helfrich<sup>2</sup>, M. Rogers<sup>2</sup>, M. Abinun<sup>3</sup>, P. Vezzoni<sup>1</sup>, A. Villa<sup>1</sup>, A. Frattini<sup>1</sup>

<sup>1</sup>*Human Genome, ITB - CNR, Segrate, Italy,* <sup>2</sup>*Bone & Musculoskeletal Programme, University of Aberdeen, Aberdeen,* <sup>3</sup>*Institute for Cellular Medicine, Faculty of Medicine, Newcastle upon Tyne, Newcastle, United Kingdom*

**Su-P214 NEW MOUSE MODELS AND MECHANISMS FOR BONE AND CARTILAGE DISORDERS**

W. Hans\*<sup>1</sup>, T. S. Lisse<sup>2</sup>, H. Fuchs<sup>1</sup>, K. Abe<sup>3</sup>, F. Thiele<sup>1</sup>, C. M. Cohrs<sup>1</sup>, V. Gailus-Durner<sup>1</sup>, M. Hrabé de Angelis<sup>1</sup>

<sup>1</sup>*Helmholtz Center Munich, German Research Center for Environmental Health GmbH, Institute of Experimental Genetics, Neuherberg, Germany,* <sup>2</sup>*National Institutes of Health, Bone and Extracellular Matrix Branch, National Institute of Child Health and Human Development, Bethesda, MD, United States,* <sup>3</sup>*Tokai University Medical School, Basic Medical Science and Molecular Medicine, Kanagawa, Japan*

**Su-P215 GENOTYPES AND HAPLOTYPES OF THE PPARGAMMA GENE ARE ASSOCIATED WITH OSTEOPOROTIC FRACTURE THROUGH MOLECULAR HETEROISIS**

T. Harsløf\*<sup>1</sup>, L. B. Husted<sup>1</sup>, M. Carstens<sup>1</sup>, L. Stenkjær<sup>1</sup>, B. L. Langdahl<sup>1</sup>

<sup>1</sup>*Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus C, Denmark*

**Su-P216 POLYMORPHISMS IN THE CHEMOKINE RECEPTOR 3 GENE ARE TESTED FOR ASSOCIATION WITH BONE MINERAL DENSITY VARIATION IN A FAMILY-BASED STUDY**

K. G. Hegarty\*<sup>1</sup>, M. Daly<sup>1</sup>, F. Shanahan<sup>2</sup>, M. Molloy<sup>3</sup>

<sup>1</sup>*Medicine,* <sup>2</sup>*Alimentary Pharmabiotic Center,* <sup>3</sup>*Department of Rheumatology and Sports Medicine, National University of Ireland, Cork, Ireland*

**Su-P217 THE T29C POLYMORPHISM IN THE SIGNAL PEPTIDE OF TRANSFORMING GROWTH FACTOR-BETA1 INCREASES SECRETION IN VITRO**

L. B. Husted\*<sup>1</sup>, L. Sørensen<sup>1</sup>, L. Stenkjær<sup>1</sup>, M. Carstens<sup>1</sup>, B. L. Langdahl<sup>1</sup>

<sup>1</sup>*Department of Endocrinology and Metabolism, Aarhus University Hospital, Århus C, Denmark*

**Genetics**

**See also: Mo-P218 - Mo-P227**

**Tu-P228 - Tu-P238**

**Su-P239 TRANSACTIVATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 BY THE C-TERMINAL DOMAIN OF PARATHYROID HORMONE-RELATED PROTEIN INDUCES OSTEOBLAST SURVIVAL**

V. Alonso\*<sup>1</sup>, A. R. de Gortazar<sup>1</sup>, J. A. Ardura<sup>1</sup>, I. Andrade<sup>1</sup>, M. V. Alvarez-Arroyo<sup>1</sup>, P. Esbrit<sup>1</sup>  
<sup>1</sup>*Bone and Mineral Metabolism Laboratory, Fundación Jiménez Díaz, Madrid, Spain*

**Su-P240 ESTROGEN INHIBITS DLK1/FA1/PREF-1 PRODUCTION: A POTENTIAL MECHANISM FOR ESTROGEN EFFECTS ON BONE AND CARTILAGE TURNOVER**

A. C. Bay-Jensen<sup>1</sup>, B. Srinivasan<sup>2</sup>, B. Abdallah<sup>1</sup>, N. Charni-Ben Tabassi<sup>3</sup>, P. Garnero<sup>3</sup>, J. M. Delaissé<sup>4</sup>, S. Khosla<sup>2</sup>, M. Kassem\*<sup>1</sup>

<sup>1</sup>*Dept. of Endocrinology and Metabolism, University of Southern Denmark, Odense C, Denmark,* <sup>2</sup>*Osteoporosis and Bone Biology research, Mayo Clinic, Rochester, United States,* <sup>3</sup>*Biomarkers, Synarc, Lyon, France,* <sup>4</sup>*Clinical Cell biology, SDU, Vejle Hospital, Vejle, Denmark*

**Su-P241 VITAMIN D METABOLISM IN FAMILIAL HYPOCALCIURIC HYPERCALCAEMIA AND PRIMARY HYPERPARATHYROIDISM.**

S. E. Christensen\*<sup>1</sup>, P. H. Nissen<sup>2</sup>, P. Vestergaard<sup>1</sup>, L. Heickendorff<sup>2</sup>, K. Brixen<sup>3</sup>, L. Mosekilde<sup>1</sup>  
<sup>1</sup>*Department of Endocrinology,* <sup>2</sup>*Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus C.,* <sup>3</sup>*Department of Endocrinology, Odense University Hospital, Odense, Denmark*

**Su-P242 VITAMIN D-METABOLISM AND PTH LEVELS SHOW A BIPHASIC SEASONAL PATTERN BUT ARE NOT CORRELATED TO OSTEOCALCIN LEVELS IN OUTPATIENTS FROM WESTERN NORWAY**

M. Christensen\*<sup>1</sup>, E. A. Lien<sup>2</sup>, B. Almås<sup>1</sup>

<sup>1</sup>*Hormone Laboratory, Haukeland University Hospital,* <sup>2</sup>*Section for Endocrinology, Institute of Medicine, University of Bergen, Bergen, Norway*

**Su-P243 BONE DENSITY (PHALANGEAL QUANTITATIVE ULTRASOUND (PQUS), SERUM 25-OH-D AND PTH LEVELS IN DIFFERENT BMI POPULATIONS**

P. De Remigis\*<sup>1</sup>, P. Ranieri<sup>1</sup>, A. De Remigis<sup>1</sup>, S. Porfiri<sup>2</sup>, A. Passerini<sup>2</sup>, L. Vianale<sup>1</sup>

<sup>1</sup>*Endocrine Unit,* <sup>2</sup>*Orhopedic Clinic, General Hospital, CHIETI, Italy*

**Su-P244 AROMATASE INHIBITION INCREASES LONGITUDINAL GROWTH AND CANCELLOUS BONE LOSS IN PREPUBERTAL FEMALE RATS**

T. De Schutter\*<sup>1</sup>, A. Postnov<sup>2</sup>, S. van Gool<sup>3</sup>, M. Karperien<sup>4</sup>, N. De Clerck<sup>1</sup>

<sup>1</sup>*Department of Biomedical Sciences,* <sup>2</sup>*Department of Physics, University of Antwerp, Antwerp, Belgium,* <sup>3</sup>*Department of Pediatrics,* <sup>4</sup>*Department of Endocrinology, Leiden University Medical Center, Leiden, Netherlands*

**Su-P245 AORTIC STIFFNESS: A REVERSIBLE MARKER OF CARDIOVASCULAR RISK IN PRIMARY HYPERPARATHYROIDISM?**

G. Fabbriani\*<sup>1</sup>, C. Leli<sup>1</sup>, G. Pucci<sup>1</sup>, G. Schillaci<sup>1</sup>, A. M. Scarponi<sup>1</sup>, N. Avenia<sup>2</sup>, M. Monacelli<sup>2</sup>, L. Callarelli<sup>1</sup>, N. Daddi<sup>2</sup>, E. Mannarino<sup>1</sup>

<sup>1</sup>Internal Medicine, Angiology and Arteriosclerotic Diseases, <sup>2</sup>AFOI-Endocrinological Surgery, University Hospital of Perugia, Perugia, Italy

**Su-P246 EFFICACY OF CHOLECALCIFEROL 800 IU SUPPLEMENTATION WITH OR WITHOUT CALCIUM SUPPLEMENTS IN PREVENTING FALLS OF THE ELDERLY PEOPLE**

G. J. D. Bergman\*<sup>1</sup>, T. Fan<sup>2</sup>, S. S. Sen<sup>2</sup>, J. P. Jansen<sup>1</sup>

<sup>1</sup>, Mapi Values, Houten, Netherlands, <sup>2</sup>Global Outcomes Research and HTA, Merck and Co., Inc, Whitehouse Station, United States

**Su-P247 EFFICACY OF CHOLECALCIFEROL 800 IU SUPPLEMENTATION WITH OR WITHOUT CALCIUM SUPPLEMENTS IN PREVENTING NON-VERTEBRAL AND HIP FRACTURES FOR WOMEN 60 YEARS AND OLDER**

G. J. D. Bergman\*<sup>1</sup>, T. Fan<sup>2</sup>, S. S. Sen<sup>2</sup>, J. P. Jansen<sup>1</sup>

<sup>1</sup>, Mapi Values, Houten, Netherlands, <sup>2</sup>Global Outcomes Research and HTA, Merck and Co., Inc, Whitehouse Station, United States

**Su-P248 BONE METABOLISM IN MARES DURING LATE PREGNANCY AND EARLY LACTATION**

N. Filipovic\*<sup>1</sup>, Z. Stojevic<sup>1</sup>, N. Prvanovic<sup>2</sup>, Z. Tucek<sup>3</sup>, V. Kusec<sup>4</sup>, B. Beer Ljubic<sup>1</sup>

<sup>1</sup>Department of Physiology and Radiobiology, <sup>2</sup>Clinic for obstetrics and reproduction, Faculty of Veterinary Medicine University of Zagreb, <sup>3</sup>, Center for animal reproduction of Croatia, <sup>4</sup>, Clinical Hospital Centre Zagreb, Zagreb, Croatia

**Su-P249 SERUM CONCENTRATION OF CALCIFICATION INHIBITOR, FETUIN A, IS NOT ASSOCIATED WITH IMT OR AOPWV IN PATIENTS WITH ESSENTIAL HYPERTENSION - PRELIMINARY RESULTS**

T. Budlewski<sup>1</sup>, A. Blach<sup>1</sup>, E. Klamczynska<sup>2</sup>, E. Franek\*<sup>1</sup>

<sup>1</sup>Dept of Endocrinology and Diabetology, <sup>2</sup>Dept of Cardiology, Central Clinical Hospital MSWiA, Warszawa, Poland

**Su-P250 SERUM ESTRADIOL IS A PREDICTOR OF BMD IN ELDERLY MEN – RESULTS FROM THE ODENSE ANDROGEN STUDY**

L. Frederiksen\*<sup>1</sup>, K. Wraae<sup>1</sup>, T. L. Nielsen<sup>1</sup>, C. Hagen<sup>1</sup>, K. Brixen<sup>1</sup>, M. Andersen<sup>1</sup>

<sup>1</sup>Endocrinology, Odense University Hospital, Odense, Denmark

**Su-P251 RELATIONSHIPS OF GHRELIN WITH BONE MINERAL DENSITY AND BONE TURNOVER MARKERS IN ELDERLY MEN**

S. Gonnelli\*<sup>1</sup>, C. Caffarelli<sup>1</sup>, K. Del Santo<sup>1</sup>, L. Tanzilli<sup>1</sup>, A. Cadirni<sup>1</sup>, C. Guerriero<sup>1</sup>, B. Lucani<sup>1</sup>, S. Campagna<sup>1</sup>, R. Nuti<sup>1</sup>

<sup>1</sup>Internal Medicine, University of Siena, Siena, Italy

**Su-P252 LACK OF VITAMIN D PROMOTES DISEASE PROGRESSION IN A GUINEA PIG MODEL OF OSTEOARTHRITIS**

M. D. Grynepas\*<sup>1</sup>, T. Hunt<sup>1</sup>, R. Kandel<sup>1</sup>, R. Vieth<sup>2</sup>, R. Renlund<sup>3</sup>

<sup>1</sup>, Samuel Lunenfeld Research Institute, <sup>2</sup>, Mount Sinai Hospital, <sup>3</sup>Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada

**Su-P253 PARATHYROID HORMONE REGULATION AND EXERCISE**

S. E. Guillemant\*<sup>1</sup>

<sup>1</sup>*Biochemistry and Nutrition, Nutrition, Environnement et Sante, Paris, France*

**More Hormones, including estrogen, vitamin D, PTHRP**

See also: **Mo-P254 - Mo-P268**

**Tu-P269 - Tu-P283**

**Osteoporosis: evaluation Su-P284 – Su-P296**

**Su-P284 A COST-UTILITY ANALYSIS OF FULL-LENGTH PARATHYROID HORMONE PTH (1-84)**

J. D. Belsey\*<sup>1</sup>, M. Asmussen<sup>2</sup>, J. Dalton<sup>3</sup>

<sup>1</sup>*Health Technology Assessment, JB Medical Ltd, Sudbury, United Kingdom,* <sup>2</sup>*International Pricing and Market Access, Nycomed, Roskilde, Denmark,* <sup>3</sup>*Medical Affairs, Pharmedica Ltd, Fewcott, United Kingdom*

**Su-P285 FEMUR ULTRASOUND (FEMUS) – A NEW METHOD FOR THE ESTIMATION OF OSTEOPOROTIC FRACTURE RISK?**

R. Barkmann\*<sup>1</sup>, S. Dencks<sup>1</sup>, A. Bremer<sup>1</sup>, P. Laugier<sup>2</sup>, F. Padilla<sup>2</sup>, K. Brixen<sup>3</sup>, J. Ryg<sup>3</sup>, C. C. Glüer<sup>1</sup>

<sup>1</sup>*Medizinische Physik, Diagnostische Radiologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany,* <sup>2</sup>*Laboratoire d'Imagerie Paramétrique, Université Pierre et Marie Curie, Paris, France,* <sup>3</sup>*Department of Endocrinology, Odense University Hospital, Odense, Denmark*

**Su-P286 BONE MINERAL DENSITY AND BODY COMPOSITION MEASURED BY DXA HALF SCAN PREDICTS TOTAL BODY VALUES**

E. Bonel\*<sup>1</sup>, C. Sole<sup>1</sup>, M. Garcia<sup>1</sup>, J. Rosales<sup>1</sup>, S. Di Gregorio<sup>1</sup>, L. del Rio<sup>1</sup>

<sup>1</sup>*Bone Densitometry, CETIR Centre M, Barcelona, Spain*

**Su-P287 DOES WRITTEN STANDARDIZED INFORMATION IMPROVE PATIENT UNDERSTANDING OF DXA-RESULTS?**

D. Brask-Rasmussen\*<sup>1</sup>, S. Cadarette<sup>2</sup>, P. Eskildsen<sup>1</sup>, B. Abrahamsen<sup>3</sup>

<sup>1</sup>*Department of Endocrinology, Køge University Hospital, Køge, Denmark,* <sup>2</sup>*Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, United States,* <sup>3</sup>*Department of Endocrinology, Gentofte University Hospital, Gentofte, Denmark*

**Su-P288 REFERENCE VALUES FOR HIP STRUCTURE ANALYSIS (HSA) IN HEALTHY YOUNG MEN - RESULTS FROM THE ODENSE ANDROGEN STUDY**

K. Brixen<sup>1</sup>, T. L. Nielsen\*<sup>1</sup>, K. Wraae<sup>1</sup>, T. L. Kelly<sup>2</sup>, C. Hagen<sup>3</sup>, M. Andersen<sup>1</sup>

<sup>1</sup>*Endocrinology, Odense University Hospital, Odense, Denmark,* <sup>2</sup>*Hologic Inc., Bedford, United States,* <sup>3</sup>*Endocrinology, Gentofte Hospital, Copenhagen, Denmark*

**Su-P289 DEGRADATION OF BONE BIOMECHANICAL PROPERTIES SECONDARY TO QUANTITATIVE AND QUALITATIVE BONE DISTURBANCES INDUCED BY ARTHRITIS IN SKG MICE**

J. Caetano-Lopes\*<sup>1</sup>, A. M. Nery<sup>2</sup>, R. Henriques<sup>3</sup>, H. Canhão<sup>4</sup>, J. Duarte<sup>5</sup>, P. Amaral<sup>6</sup>, M. Vale<sup>7</sup>, R. Moura<sup>1</sup>, P. A. Pereira<sup>1</sup>, P. Weinmann<sup>1</sup>, M. Souto-Carneiro<sup>8</sup>, P. Rego<sup>7</sup>, J. Monteiro<sup>7</sup>, S. Sakagushi<sup>9</sup>, L. Graça<sup>5</sup>, M. Viana Queiroz<sup>10</sup>, M. F. Vaz<sup>6</sup>, J. E. Fonseca<sup>4</sup>

<sup>1</sup>*Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina,*

<sup>2</sup>Rheumatology Research Unit and ICEMS and Departamento de Engenharia de Materiais, Instituto de Medicina Molecular and Instituto Superior Técnico, <sup>3</sup>BioImaging Unit, Instituto de Medicina Molecular, Faculdade de Medicina, <sup>4</sup>Rheumatology Research Unit, Instituto de Medicina Molecular and Santa Maria Hospital, <sup>5</sup>Cellular Immunology Unit, Instituto de Medicina Molecular and Instituto Gulbenkian de Ciência, <sup>6</sup>ICEMS and Departamento de Engenharia de Materiais, Instituto Superior Técnico, <sup>7</sup>Serviço de Ortopedia, Hospital de Santa Maria, Lisbon, <sup>8</sup>Systems Immunology group, Instituto Gulbenkian de Ciência, Oeiras, Portugal, <sup>9</sup>Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto, Japan, <sup>10</sup>Serviço de Reumatologia, Santa Maria Hospital, Lisbon, Portugal

**Su-P290 ARE THERE DIFFERENCES AMONG WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS DEPENDING ON THE PRESENCE OF VERTEBRAL FRACTURES?**

D. Cerdà\*<sup>1</sup>, P. Peris<sup>2</sup>, A. Monegal<sup>2</sup>, C. Albaladejo<sup>3</sup>, M. Martínez<sup>2</sup>, F. Pons<sup>4</sup>, M. Martínez de Osaba<sup>5</sup>, X. Surís<sup>1</sup>, N. Guañabens<sup>2</sup>

<sup>1</sup>Rheumatology, Hospital General de Granollers, Granollers, <sup>2</sup>Rheumatology, Hospital Clínic, <sup>3</sup>Rheumatology, CAP Manso, <sup>4</sup>Nuclear Medicine, <sup>5</sup>Hormonal Laboratory, Hospital Clínic, Barcelona, Spain

**Su-P291 BONE MINERAL DENSITY AND MARKERS OF BONE TURNOVER IN MEN WITH IDIOPATHIC OR HYPOGONADAL OSTEOPOROSIS**

J. H. Krege\*<sup>1</sup>, H. Oertel<sup>1</sup>, K. See<sup>1</sup>, G. P. Dalsky<sup>1</sup>

<sup>1</sup>Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, United States

**Su-P292 PERI-TROCHANTERIC FAT CUSHION EVALUATED BY DXA AS HIP FRACTURE PROTECTOR**

L. del Rio\*<sup>1</sup>, S. Di Gregorio<sup>1</sup>, M. Garcia<sup>1</sup>, E. Bonel<sup>1</sup>, C. Sole<sup>1</sup>, J. Rosales<sup>1</sup>

<sup>1</sup>Bone Densitometry, CETIR Centre Mèdic, Barcelona, Spain

**Su-P293 HIP-FRACTURE TYPE AND FUNCTIONAL OUTCOME IN ELDERLY WOMEN**

M. Di Monaco\*<sup>1</sup>, F. Vallero<sup>1</sup>, R. Di Monaco<sup>2</sup>, R. Tappero<sup>3</sup>, A. Cavanna<sup>1</sup>

<sup>1</sup>Osteoporosis Research Center, Presidio Sanitario San Camillo, <sup>2</sup>SRF, Società Ricerca e Formazione, <sup>3</sup>Division of Physical Medicine and Rehabilitation, Presidio Sanitario San Camillo, Torino, Italy

**Su-P294 THE QUALITY OF LIFE ASSESSMENT IN A GROUP OF PATIENTS WITH OSTEOPOROSIS IN FELIX SPA ROMANIA USING QUALEFFO 41 QUESTIONNAIRE**

D. M. Farcas\*<sup>1</sup>, L. O. Burta<sup>2</sup>, C. Moldovan<sup>3</sup>, C. Suteu<sup>4</sup>, F. Tirlea<sup>5</sup>, A. M. Tiurbe<sup>6</sup>

<sup>1</sup>Physical Rehabilitation, <sup>2</sup>Microbiology, Clinical Laboratory, <sup>3</sup>Internal Medicine, <sup>4</sup>Epidemiology, University of Oradea - Faculty of Medicine and Pharmacy, <sup>5</sup>Internal Medicine, University of Oradea - Faculty of Medicine and Pharmacy, Romania, Oradea, <sup>6</sup>General Medicine, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj Napoca, Romania

**Su-P295 ADVANCED IMAGING ASSESSMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS (GIO)**

B. B. Kalpakcioglu\*<sup>1</sup>, K. Engelke<sup>2</sup>, H. K. Genant<sup>3</sup>

<sup>1</sup>Department of Physical Therapy and Rehabilitation, Haydarpasa Numune Hospital, Istanbul, Turkey, <sup>2</sup>Department of Medical Physics, University of Erlangen-Nürnberg, Erlangen,

Germany, <sup>3</sup>Depts of Radiology and Medicine, University of California, San Francisco, United States

**Su-P296 CLINICAL EVALUATION OF A NOVEL FRAGMENTS ABSORBED IMMUNOCAPTURE ENZYMATIC ASSAY (FAICEA) FOR TRACP 5B**

R. A. Hannon\*<sup>1</sup>, K. E. Naylor<sup>1</sup>, J. A. Clowes<sup>2</sup>, R. Eastell<sup>1</sup>

<sup>1</sup>Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom,

<sup>2</sup>Endocrinology and Rheumatology, Mayo Clinic, Rochester, United States

**Osteoporosis: evaluation**

See also: **Mo-P297 - Mo-P310**

**Tu-P311 - Tu-P324**

**Osteoporosis: pathophysiology and epidemiology** **Su-P325 – Su-P347**

**Su-P325 EVALUATION OF QUALITY OF LIFE AND INCIDENCE OF VERTEBRAL FRACTURE IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA**

G. Pagano Mariano\*<sup>1</sup>, M. Caminiti<sup>1</sup>

<sup>1</sup>U.O.S. Rheumatology - Center of Osteoporosis., Azienda Ospedaliera Presidio Morelli, Reggio Calabria, Italy

**Su-P326 INFLUENCE OF A HISTORY OF HIP FRACTURE IN FIRST-DEGREE RELATIVES ON FRACTURES IN 60+ YEAR OLD MEN**

M. F. Nielsen\*<sup>1</sup>, K. Brixen<sup>1</sup>, B. Abrahamsen<sup>2</sup>

<sup>1</sup>Dept of Endocrinology, Odense Univ Hospital, Odense, <sup>2</sup>Dept of Medicine F, Copenhagen University Hospital Gentofte, Hellerup, Denmark

**Su-P327 DISTRIBUTION OF RISK FACTORS FOR FRACTURE IN WOMEN WITH AND WITHOUT A FRACTURE HISTORY: A REGIONAL COMPARISON. THE GLOBAL LONGITUDINAL REGISTRY OF OSTEOPOROSIS IN WOMEN**

J. Adachi\*<sup>1</sup>, J. Compston<sup>2</sup>, C. Cooper<sup>3</sup>, A. Díez-Pérez<sup>4</sup>, F. Hooven<sup>5</sup>, J. Netelenbos<sup>6</sup>, R. Dedrick<sup>5</sup>, C. Roux<sup>7</sup>

<sup>1</sup>St. Joseph's Hospital, McMaster University, Ontario, Canada, <sup>2</sup>University of Cambridge, Addenbrooke's Hospital, Cambridge, <sup>3</sup>MRC Environmental Epidemiology Unit, Southampton General Hospital, Southampton, United Kingdom, <sup>4</sup>Autonomous University of Barcelona, Hospital Del Mar, Barcelona, Spain, <sup>5</sup>Center for Outcomes Research, UMASS Medical School, Worcester, United States, <sup>6</sup>Department of Endocrinology, VU University Medical Center, Amsterdam, Netherlands, <sup>7</sup>Centre D'Evaluation Des Maladies Osseuses, Hopital Cochin, Paris, France

**Su-P328 OVEREXPRESSION OF OSTEOBLAST IGF-I BLUNTS THE DELETERIOUS EFFECTS OF LOW PROTEIN INTAKE ON BONE STRENGTH**

P. Ammann\*<sup>1</sup>, B. E. Kream<sup>2</sup>, C. Rosen<sup>3</sup>, R. Rizzoli<sup>1</sup>

<sup>1</sup>Division of Bone Diseases, Department of Rehabilitation and Geriatrics, Geneva, Switzerland,

<sup>2</sup>Department of Medicine AM-047, University of Connecticut Health Center, Farmington, <sup>3</sup>St Josephs Hospital, Maine Center for Osteoporosis Research, Bangor, United States

**Su-P329 PROPENSITY TO ACCUMULATE BONE MICRODAMAGES IS INCREASED IN ADULT FEMALE RATS FED AN ISOCALORIC LOW PROTEIN DIET**

V. Dubois-Ferrière<sup>1</sup>, R. Rizzoli<sup>1</sup>, P. Ammann\*<sup>1</sup>

<sup>1</sup>*Division of Bone Diseases, Department of Rehabilitation and Geriatrics, Geneva, Switzerland*

**Su-P330 DECREASED ACTIVITY OF LACTASE PHLORIZIN HYDROLASE AND BONE MINERAL DENSITY**

K. Bácsi\*<sup>1</sup>, J. P. Kósa<sup>1</sup>, B. Balla<sup>1</sup>, Á. Lazáry<sup>1</sup>, Z. Nagy<sup>1</sup>, I. Takács<sup>1</sup>, G. Speer<sup>1</sup>, P. Lakatos<sup>1</sup>

<sup>1</sup>*First Department of Internal Medicine, Semmelweis University, Budapest, Hungary*

**Su-P331 VALIDATION OF A CLINICAL DEFINITION FOR FRAGILITY FRACTURE**

J. P. Brown\*<sup>1</sup>, L. Bessette<sup>1</sup>, S. Jean<sup>2</sup>, S. K. Davison<sup>1</sup>, L. Ste-Marie<sup>3</sup>

<sup>1</sup>*Rhumatologie et immunologie, Centre de recherche du CHUL, <sup>2</sup>Systeme de soins et services, Institut national de santé publique du Québec, Québec, <sup>3</sup>Laboratoire des maladies osseuses métaboliques, CHUM - Hôpital St-Luc, Montreal, Canada*

**Su-P332 THE RELATIONSHIP BETWEEN BONE MINERAL DENSITY AND ATHEROSCLEROTIC PARAMETERS IN POSTMENOPAUSAL WOMEN WITH DIABETES**

D. Byun\*<sup>1</sup>, J. Kim<sup>1</sup>, M. Roh<sup>1</sup>, J. Jung<sup>1</sup>, J. Mok<sup>1</sup>, Y. Kim<sup>1</sup>, H. Park<sup>1</sup>, C. Kim<sup>1</sup>, S. Kim<sup>1</sup>, K. Suh<sup>1</sup>, M. Yoo<sup>1</sup>, M. Kang<sup>2</sup>

<sup>1</sup>*Endocrinology, Soonchunhyang University Hospital, <sup>2</sup>Endocrinology, Catholic University Hospital, Seoul, South Korea*

**Su-P333 ASSESSMENT OF RISK FACTORS FOR OSTEOPOROSIS AND PREDICTION OF 10YR FEMORAL FRACTURE RISK IN ELDERLY WOMEN FROM CANOSA OF PUGLIA**

M. Calitro\*<sup>1</sup>, G. Pietrapertosa<sup>2</sup>, D. Novelli<sup>2</sup>, L. Turchiarulo<sup>3</sup>, V. Frisardi<sup>2</sup>, M. Ciciriello<sup>2</sup>, D. Pietrapertosa<sup>2</sup>

<sup>1</sup>*Geriatric Division, Hospital of Canosa, Canosa of Puglia, <sup>2</sup>Geriatric Division, Hospital of Canosa, Canosa, <sup>3</sup>Cardiology Unit, Hospital of Martinafranca, Martinafranca, Italy*

**Su-P334 OESTROGEN DEFICIENCY, BUT NOT THE LOW BONE MASS, INDUCES CARTILAGE DAMAGE IN HEALTHY KNEES IN AN EXPERIMENTAL MODEL IN RABBITS**

S. Castañeda\*<sup>1</sup>, E. Calvo<sup>2</sup>, R. Largo<sup>2</sup>, M. Bellido<sup>2</sup>, C. Gómez-Vaquero<sup>3</sup>, M. Álvarez-Soria<sup>2</sup>, G. Herrero-Beaumont<sup>2</sup>

<sup>1</sup>*Rheumatology Department, Hospital de La Princesa, <sup>2</sup>Joint and Bone Research Unit, Fundación Jiménez Díaz, Madrid, <sup>3</sup>Rheumatology Department, Hospital de Bellvitche, Barcelona, Spain*

**Su-P335 BONE REGENERATION DURING OSTEOPOROSIS**

N. V. Dedukh\*<sup>1</sup>, O. A. Nikolchenko<sup>2</sup>, I. O. Batura<sup>1</sup>

<sup>1</sup>*laboratory of Connective Tissue Morphology, <sup>2</sup>laboratory of Experimental Modelling, Sytenko Institute of Spine and Joint Pathology Ukrainian Academy of Medical Sciences, Kharkiv, Ukraine*

**Su-P336 BONE REPAIR AT HYPOTHYROIDISM**

N. V. Dedukh\*<sup>1</sup>, N. O. Ashukina<sup>1</sup>

<sup>1</sup>*laboratory of Connective Tissue Morphology, Sytenko Institute of Spine and Joint Pathology  
Ukrainian Academy of Medical Sciences, Kharkiv, Ukraine*

**Su-P337 REGIONAL DIFFERENCES IN THE MANAGEMENT OF  
OSTEOPOROSIS: EUROPE VS OTHER GEOGRAPHIC REGIONS. THE GLOBAL  
LONGITUDINAL REGISTRY OF OSTEOPOROSIS IN WOMEN**

A. Diez-Perez\*<sup>1</sup>, S. Adami<sup>2</sup>, S. Boonen<sup>3</sup>, J. Pfeilschifter<sup>4</sup>, K. Saag<sup>5</sup>, P. Sambrook<sup>6</sup>, R. Dedrick<sup>7</sup>,  
P. Delmas<sup>8</sup>

<sup>1</sup>*Hospital del Mar, Autonomous University of Barcelona, Barcelona, Spain,* <sup>2</sup>*Department of  
Rheumatology, University of Verona, Verona, Italy,* <sup>3</sup>*Division of Geriatric Medicine, Leuven  
University Center for Metabolic Bone Diseases, Leuven, Belgium,* <sup>4</sup>*Medizinische Klinik I,  
Lutherhaus, Essen, Germany,* <sup>5</sup>*Division of Clinical Immunology and Rheumatology, University  
of Alabama, Birmingham, United States,* <sup>6</sup>*Royal North Shore Hospital, University of Sydney,  
Sydney, Australia,* <sup>7</sup>*Center for Outcomes Research, UMASS Medical School, Worcester, United  
States,* <sup>8</sup>*Department of Rheumatology, Hôpital Edouard Herriot, Lyon, France*

**Su-P338 THE CHANGE IN BIOCHEMICAL BONE MARKERS AFTER 6  
MONTHS OF STRONTIUM RANELATE IN ELDERLY WOMEN AND MEN WITH  
REDUCED BONE MINERAL DENSITY**

B. H. Durham\*<sup>1</sup>, A. A. Joshi<sup>2</sup>, A. M. Ahmed<sup>2</sup>, J. P. Vora<sup>2</sup>, W. D. Fraser<sup>1</sup>

<sup>1</sup>*Clinical Chemistry and Metabolic Medicine,* <sup>2</sup>*Diabetis and Endocrinology, Royal Liverpool  
University Hospital, Liverpool, United Kingdom*

**Su-P339 VALIDITY AND REPRODUCIBILITY OF QUESTIONNAIRE ABOUT  
PREVENTIVE BEHAVIORS AMONG FRENCH AND SPANISH POST-  
MENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE CALCIUM AND  
VITAMIN INTAKE (CAVIT) STUDY**

T. Fan\*<sup>1</sup>, S. C. Bolge<sup>2</sup>, G. Nocea<sup>3</sup>, S. S. Sen<sup>4</sup>

<sup>1</sup>*Global Outcomes Research and HTA, Merck and Co., Inc, Whitehouse Station,* <sup>2</sup>*Outcomes  
Research, Consumer Health Sciences, Princeton, United States,* <sup>3</sup>*Outcomes Research, MSD  
Spain, Madrid, Spain,* <sup>4</sup>*Global Outcomes Research & HTA, Merck & Co., Inc., Whitehouse  
Station, United States*

**Su-P340 DIETARY AND SUPPLEMENTAL CALCIUM INTAKE AND DIETARY  
VITAMIN D INTAKE AMONG POST-MENOPAUSAL WOMEN WITH  
OSTEOPOROSIS IN FRANCE: CALCIUM AND VITAMIN INTAKE STUDY**

S. Czernichow\*<sup>1</sup>, T. Fan<sup>2</sup>, S. C. Bolge<sup>3</sup>, G. Nocea<sup>4</sup>, S. S. Sen<sup>5</sup>

<sup>1</sup>*INSERM U557, Centre de Recherche en Nutrition humaine, IdF, University Paris XIII &  
Public Health Department, Avicenne Hospital (AP-HP), 74, rue Marcel Cachin, 93017  
Bobigny., France,* <sup>2</sup>*Global Outcomes Research and HTA, Merck and Co., Inc, Whitehouse  
Station,* <sup>3</sup>*Outcomes Research, Consumer Health Sciences, Princeton, United States,* <sup>4</sup>*Outcomes  
Research, Merck Sharp & Dohme, España, Madrid, Spain,* <sup>5</sup>*Global Outcomes Research &  
HTA, Merck & Co., Inc., Whitehouse Station, United States*

**Su-P341 DECREASED BONE FRACTURE PREVALENCE IN POLLEN  
ALLERGIC MEN**

V. Ferencz\*<sup>1</sup>, S. Meszaros<sup>1</sup>, A. Palinkas<sup>1</sup>, E. Csupor<sup>2</sup>, E. Toth<sup>3</sup>, K. Bors<sup>4</sup>, E. Hosszu<sup>5</sup>, A. Falus<sup>6</sup>,  
C. Horvath<sup>1</sup>

<sup>1</sup>*1st Department of Internal Medicine, Semmelweis University, <sup>2</sup>Health Service, Budavar Local Authorities, Budapest, <sup>3</sup>Department of Rheumatology, Ferenc Flor Country Hospital, Kistarcsa, <sup>4</sup>Regional Osteoporosis Centre Ferencvaros, Ferencvaros Local Authorities, <sup>5</sup>2nd Department of Pediatrics, <sup>6</sup>Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary*

**Su-P342 RELATIONSHIPS BETWEEN BASELINE BONE TURNOVER, SUBSEQUENT VERTEBRAL FRACTURE AND BONE LOSS**

J. Finigan\*<sup>1</sup>, C. C. Glüer<sup>2</sup>, D. Felsenberg<sup>3</sup>, D. Reid<sup>4</sup>, C. Roux<sup>5</sup>, R. Eastell<sup>1</sup>

<sup>1</sup>*Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, <sup>2</sup>Diagnostische Radiologie, Universitätsklinikum Schleswig-Holstein, Kiel, <sup>3</sup>ZMK, Charité Universitätsmedizin, Berlin, Germany, <sup>4</sup>Dept of Medicine & Therapeutics, University of Aberdeen, Aberdeen, United Kingdom, <sup>5</sup>Faculté de Médecine, René Descartes University, Paris, France*

**Su-P343 EFFECTS OF AZOLE ANTIFUNGAL DRUGS ON BONE MECHANICAL PROPERTIES IN RATS**

J. Folwarczna\*<sup>1</sup>, R. Pilch<sup>1</sup>, E. Lis<sup>1</sup>, M. Gancarska<sup>1</sup>, S. Sajdak<sup>1</sup>, W. Włodarczyk-Węgrzyn<sup>1</sup>, H. I. Trzeciak<sup>1</sup>, W. Janiec<sup>1</sup>

<sup>1</sup>*Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland*

**Su-P344 HIP STRUCTURE IS RELATED TO MUSCLE MASS OF THE THIGH IN HEALTHY YOUNG MEN - RESULTS FROM THE ODENSE ANDROGEN STUDY**

L. Frederiksen\*<sup>1</sup>, N. Nissen<sup>1</sup>, T. L. Nielsen<sup>1</sup>, K. Wraae<sup>1</sup>, C. Hagen<sup>1</sup>, M. Andersen<sup>1</sup>, K. Brixen<sup>1</sup>

<sup>1</sup>*Department of Endocrinology, Odense University Hospital, Odense, Denmark*

**Su-P345 MICROSTRUCTURE OF CORTICAL BONE AS STUDIED BY RAMAN SPECTROSCOPY (COMPOSITION VS ORIENTATION)**

S. Gamsjäger\*<sup>1</sup>, M. Kazanci<sup>2</sup>, I. Manjubala<sup>2</sup>, H. S. Gupta<sup>2</sup>, P. Roschger<sup>1</sup>, E. P. Paschalis<sup>1</sup>, K. Klaushofer<sup>1</sup>, P. Fratzl<sup>2</sup>

<sup>1</sup>*Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, Vienna, Austria, <sup>2</sup>Departement of Biomaterials, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany*

**Su-P346 LIFE-STYLE RISK FACTORS FOR OSTEOPOROSIS AND FRACTURE RATE**

A. E. Georgiadis\*<sup>1</sup>, I. Piscontaki<sup>1</sup>, S. Apostolidis<sup>1</sup>, K. Likipoudis<sup>1</sup>, X. Lainas<sup>1</sup>, K. Minopoulos<sup>1</sup>, I. Pappas<sup>1</sup>, S. Dimoudis<sup>1</sup>, G. Valasis<sup>1</sup>

<sup>1</sup>*Osteoporosis Center, Lito Gynecological Hospital, Athens, Greece*

**Su-P347 THE IMPACT OF TYPE 2 DIABETES MELLITUS ON THE ASSOCIATION OF BONE MINERAL DENSITY WITH BODY COMPOSITION**

D. Hadjidakis\*<sup>1</sup>, A. Mylonakis<sup>1</sup>, I. I. Androulakis<sup>1</sup>, A. E. Raptis<sup>1</sup>, M. Peppas<sup>1</sup>, A. Papaefstathiou<sup>1</sup>, T. Economopoulos<sup>1</sup>, S. A. Raptis<sup>1</sup>

<sup>1</sup>*Endocrine Unit, 2nd Department of Internal Medicine-Propaedeutic, Research Institute and Diabetes Ce, Athens University, «Attikon» and «Evgenidion» University Hospitals, Athens, Greece*

**Osteoporosis: pathophysiology and epidemiology**

See also: **Mo-P348 - Mo-P370**  
**Tu-P371 - Tu-P393**

**Osteoporosis: treatment** **Su-P394 – Su-P430**

**Su-P394 SUBTROCHANTERIC FEMUR FRACTURE IN PATIENTS TREATED WITH ORAL BISPHOSPHONATES: A NATIONAL REGISTER STUDY**

B. Abrahamsen\*<sup>1</sup>, P. Eiken<sup>2</sup>

<sup>1</sup>Dept of Medicine F, Copenhagen University Hospital Gentofte, Hellerup, <sup>2</sup>Dept of Medicine, Nordsjællands Hospital Hillerød, Hillerød, Denmark

**Su-P395 INITIATION OF ANTI-OSTEOPOROTIC MEDICATIONS IN PATIENTS WITH RECENT FRACTURES**

B. Abrahamsen\*<sup>1</sup>, C. Roerholt<sup>1</sup>, P. Eiken<sup>2</sup>

<sup>1</sup>Dept of Medicine F, Copenhagen University Hospital Gentofte, Hellerup, <sup>2</sup>Dept of Medicine, Nordsjællands Hospital Hillerød, Hillerød, Denmark

**Su-P396 SIGNIFICANT REDUCTION IN NON-VERTEBRAL FRACTURES WITH INTRAVENOUS IBANDRONATE INJECTION: POST-HOC ANALYSIS OF THE DIVA TRIAL**

J. D. Adachi\*<sup>1</sup>, P. Sambrook<sup>2</sup>, C. Barr<sup>3</sup>, S. Papapoulos<sup>4</sup>

<sup>1</sup>Department of Medicine, McMaster University, Hamilton, Canada, <sup>2</sup>Institute of Bone and Joint Research, University of Sydney, Sydney, Australia, <sup>3</sup>PBMA, Roche Laboratories Inc, Nutley, United States, <sup>4</sup>Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, Netherlands

**Su-P397 SAFETY AND TOLERABILITY OF BAZEDOXIFENE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM A 3-YEAR, RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED CLINICAL TRIAL**

J. D. Adachi\*<sup>1</sup>, C. H. Chesnut<sup>2</sup>, J. P. Brown<sup>3</sup>, C. Christiansen<sup>4</sup>, L. A. Russo<sup>5</sup>, C. E. Fernandes<sup>6</sup>, J. C. Menegoci<sup>7</sup>, A. Kung<sup>8</sup>, A. A. Chines<sup>9</sup>, L. Bessac<sup>9</sup>

<sup>1</sup>, St. Josephs Hospital - McMaster University, Hamilton, Ontario, Canada, <sup>2</sup>, University of Washington Medical Center, Seattle, WA, United States, <sup>3</sup>, Laval University, Quebec City, Quebec, Canada, <sup>4</sup>, Center for Clinical and Basic Research (CCBR), Ballerup, Denmark, <sup>5</sup>, CCBR, Rio de Janeiro, <sup>6</sup>, Women's Health and Wellness Institute, <sup>7</sup>, Pontifícia Universidade Católica de São Paulo, São Paulo, Brazil, <sup>8</sup>, University of Hong Kong, Hong Kong, China, <sup>9</sup>, Wyeth Research, Collegeville, PA, United States

**Su-P398 RAPID SUPPRESSION OF SERUM CTX WITH ONCE-MONTHLY ORAL IBANDRONATE**

S. Adami\*<sup>1</sup>, J. Boisdron<sup>2</sup>, S. Silverman<sup>3</sup>

<sup>1</sup>Department of Rheumatology, University of Verona, Verona, Italy, <sup>2</sup>PBMA, F. Hoffmann-La Roche Ltd, Basel, Switzerland, <sup>3</sup>Medicine and Rheumatology, Cedars-Sinai/UCLA, Beverly Hills, United States

**Su-P399 EFFECT OF CHRONIC STRONTIUM ADMINISTRATION ON BONE MINERAL CONTENT AND DENSITY**

J. E. T. Andersen<sup>1</sup>, S. R. Sørensen<sup>1</sup>, A. C. Raffalt<sup>1</sup>, J. B. Jensen<sup>1</sup>, S. Christgau\*<sup>1</sup>

<sup>1</sup>Chemistry, Technical University of Denmark, Kgs. Lyngby, Denmark

**Su-P400 PREFERENCES FROM 500 POST-MENOPAUSAL OSTEOPOROSIS PATIENTS FOR ADMINISTRATION OF PTH TREATMENT**

M. Asmussen\*<sup>1</sup>, C. L. Benhamou<sup>2</sup>, O. Törring<sup>3</sup>, S. Minisola<sup>4</sup>, L. H. Hyldstrup<sup>5</sup>

<sup>1</sup>International Pricing and Market Access, Nycomed, Roskilde, Denmark, <sup>2</sup>Unité de Rhumatologi, Centre Hospitalier Régional d'Orléans, Orleans Cedex, France, <sup>3</sup>Institution of Clinical Science and Education Sodertorsjukhuset, Karolinska Institutet, Stockholm, Sweden, <sup>4</sup>Dipartimento di Medicina Interna, Policlinico Umberto I, Rome, Italy, <sup>5</sup>International Medical Scientific Strategy & Medical Marketing, Nycomed, Roskilde, Denmark

**Su-P401 SECONDARY OSTEOPOROSIS AND TEMPOROMANDIBULAR JOINT DISORDER – A THREE-YEARS FOLLOW UP REPORTED CASE**

T. Badel\*<sup>1</sup>, M. Marotti<sup>2</sup>, J. Keros<sup>3</sup>, V. Carek<sup>1</sup>, L. Krapac<sup>4</sup>, S. Kraljeviæ Šimunkoviæ<sup>1</sup>

<sup>1</sup>Department of Prosthodontics, School of Dental Medicine, University of Zagreb, <sup>2</sup>Department of diagnostic and interventional Radiology, Clinical Hospital “Sestre milosrdnice”, University of Zagreb, <sup>3</sup>Department of Dental Anthropology, School of Dental Medicine, University of Zagreb, <sup>4</sup>Department for Rheumatic Diseases, Outpatient Center for Rheumatic Diseases, ½dr. Drago Èop½, Zagreb, Croatia

**Su-P402 A NATIONAL CLINICAL AUDIT OF STANDARDS IN THE MANAGEMENT OF FALL-RELATED FRAGILITY FRACTURES PRESENTING TO TRAUMA UNITS IN ENGLAND, WALES AND NORTHERN IRELAND**

J. R. Bayly\*<sup>1</sup>, J. Husk<sup>2</sup>, J. Potter<sup>2</sup>, F. C. Martin<sup>2</sup>

<sup>1</sup>Faculty of Education, Health and Sciences, University of Derby, Derby, <sup>2</sup>Clinical Effectiveness and Evaluation Unit, Royal College of Physicians, London, United Kingdom

**Su-P403 MANAGING OSTEOPOROSIS IN UK GENERAL PRACTICE: RESULTS FROM A NATIONAL EVALUATION USING THE QRESEARCH DATABASE**

J. R. Bayly\*<sup>1</sup>, J. Potter<sup>2</sup>, J. Fenty<sup>3</sup>, C. Parker<sup>3</sup>, T. Masud<sup>1</sup>, J. Hippisley-Cox<sup>3</sup>

<sup>1</sup>Faculty of Education, Health and Sciences, University of Derby, Derby, <sup>2</sup>Clinical Effectiveness and Evaluation Unit, Royal College of Physicians, London, <sup>3</sup>QRESEARCH, University of Nottingham, Nottingham, United Kingdom

**Su-P404 STRONTIUM ADSORPTION AND DESORPTION ON HYDROXYAPATITE CRYSTALS IN VITRO**

J. Beuvelot\*<sup>1</sup>, R. Filmon<sup>1</sup>, M. F. Baslé<sup>1</sup>, D. Chappard<sup>1</sup>

<sup>1</sup>INSERM, U 922, Faculté de Médecine, Angers, France

**Su-P405 THE SKELETAL RESPONSE TO ZOLEDRONIC ACID IS NOT AFFECTED BY RENAL IMPAIRMENT**

S. Boonen\*<sup>1</sup>, D. Black<sup>2</sup>, D. Sellmeyer<sup>2</sup>, E. F. Eriksen<sup>3</sup>, H. Bone<sup>4</sup>, A. Skag<sup>5</sup>, S. Giannini<sup>6</sup>, K. Lippuner<sup>7</sup>, P. Mesenbrink<sup>8</sup>, P. Miller<sup>9</sup>

<sup>1</sup>University Center for Metabolic Bone Diseases and Division of Geriatric Medicine, Katholieke Universiteit Leuven, Leuven, Belgium, <sup>2</sup>Department of Epidemiology and Biostatistics, University of California, San Francisco, United States, <sup>3</sup>Clinical Research and Development, Novartis Pharma AG, Basel, Switzerland, <sup>4</sup>Director, Michigan Bone and Mineral Clinic, Detroit, United States, <sup>5</sup>Department of Internal Medicine, Center for Clinical Trials, Bergen, Norway, <sup>6</sup>Azienda Ospedaliera, University of Padova, Padova, Italy, <sup>7</sup>Osteoporosis Policlinic,

University Hospital, Berne, Switzerland, <sup>8</sup>Department of Biostatistics, Novartis Pharmaceuticals Corporation, New Jersey, <sup>9</sup>Medical Director, Colorado Center for Bone Research, Colorado, United States

**Su-P406      RESPONSIVENESS OF BONE TURNOVER MARKERS TO TERIPARATIDE IS GREATER AND EARLIER FOLLOWING TREATMENT WITH RISEDRONATE COMPARED WITH ALENDRONATE: THE OPTAMISE STUDY**

S. Boonen\*<sup>1</sup>, P. D. Delmas<sup>2</sup>, N. B. Watts<sup>3</sup>, R. Lindsay<sup>4</sup>, P. Miller<sup>5</sup>, J. Stewart<sup>6</sup>, J. P. Bilezikian<sup>7</sup>  
<sup>1</sup>Department of Experimental Medicine, Katholieke Universiteit Leuven, Leuven, Belgium, <sup>2</sup>INSERM Research Unit 831 and, Universite de Lyon, Lyon, France, <sup>3</sup>Director, University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati, <sup>4</sup>Regional Bone Center, Helen Hayes Hospital and Columbia University, West Haverstraw, <sup>5</sup>Director, Colorado Center for Bone Research, Lakewood, United States, <sup>6</sup>Biostatistics, sanofi-aventis, Laval, Canada, <sup>7</sup>Division of Endocrinology, Metabolic Bone Diseases Unit, Columbia University College of Physicians and Surgeons, New York, United States

**Su-P407      ASSESSMENT OF OSTEONAL POROSITY IN PAIRED ILIAC CREST BIOPSIES OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS BY 3D MICRO-CT: EFFECT OF RISEDRONATE TREATMENT**

B. Borah<sup>1</sup>, T. Dufresne\*<sup>2</sup>, J. Nurre<sup>2</sup>, P. Chmielewski<sup>2</sup>, R. Phipps<sup>2</sup>, M. Lundy<sup>2</sup>, L. Wagner<sup>2</sup>, M. Bouxsein<sup>3</sup>, E. Seeman<sup>4</sup>  
<sup>1</sup>Procter and Gamble Pharmaceuticals, New Drug Development, <sup>2</sup>Procter & Gamble, Mason, OH, <sup>3</sup>Ortho Biomechanics Lab., Harvard Medical School, Boston, United States, <sup>4</sup>Austin Health, University of Melbourne, Melbourne, Australia

**Su-P408      OSTEOPOROSIS THERAPY FOLLOWING BONE DENSITOMETRY - PATIENT EXPECTATIONS AS DETERMINANTS OF DRUG INITIATION AND PERSISTENCE**

D. Brask-Rasmussen\*<sup>1</sup>, S. Cadarette<sup>2</sup>, P. Eskildsen<sup>1</sup>, B. Abrahamsen<sup>3</sup>  
<sup>1</sup>Department of Endocrinology, Køge University Hospital, Køge, Denmark, <sup>2</sup>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, United States, <sup>3</sup>Department of Endocrinology, Gentofte University Hospital, Gentofte, Denmark

**Su-P409      FACTORS INFLUENCING THE DIAGNOSIS AND THE TREATMENT OF OSTEOPOROSIS FOLLOWING A FRAGILITY FRACTURE**

J. P. Brown\*<sup>1</sup>, L. Bessette<sup>1</sup>, S. Jean<sup>2</sup>, S. K. Davison<sup>1</sup>, L. Ste-Marie<sup>3</sup>  
<sup>1</sup>Rhumatologie et immunologie, Centre de recherche du CHUL, <sup>2</sup>Systemes de soins et services, Institut national de santé publique du Québec, Québec, <sup>3</sup>Laboratoire des maladies osseuses métaboliques, CHUM - Hôpital St-Luc, Montreal, Canada

**Su-P410      OUTCOMES IN ELDERLY WITH PROXIMAL FEMORAL OR HUMERAL FRACTURES TREATED IN AN ORTHOGERIATRIC REHABILITATION UNIT**

G. A. Carmona\*<sup>1</sup>, R. R. Rizzoli<sup>1</sup>, P. P. Ammann<sup>1</sup>  
<sup>1</sup>Rehabilitation et Gériatrie, Hôpitaux Universitaire de Genève, Thônex, Switzerland

**Su-P411      OUTCOMES FROM A PATIENT EDUCATIONAL PROGRAM IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN TREATED WITH TERIPARATIDE**

R. Larrainzar\*<sup>1</sup>, A. Aragon<sup>2</sup>, M. Rentero<sup>3</sup>, A. Lopez<sup>4</sup>, M. Casillas<sup>3</sup>  
<sup>1</sup>Orthopedic Surgery Department, Hospital de Vallecas, <sup>2</sup>Rheumatology Department, Hospital de Getafe, Madrid, <sup>3</sup>Medical Department, Lilly SA, Alcobendas, <sup>4</sup>Rheumatology Department, SOS Assistance Española, S.A, Madrid, Spain

**Su-P412 THE CATHEPSIN K INHIBITOR AAE581 INDUCES MORPHOLOGICAL CHANGES IN OSTEOCLASTS OF TREATED PATIENTS**

D. Chappard\*<sup>1</sup>, H. Libouban<sup>1</sup>, L. Mindeholm<sup>2</sup>, M. F. Baslé<sup>1</sup>, E. Legrand<sup>3</sup>, M. Audran<sup>3</sup>  
<sup>1</sup>INSERM, U 922, Faculté de Médecine, Angers, France, <sup>2</sup>Novartis Pharma AG, Basel, Switzerland, <sup>3</sup>INSERM, U 922, Service de Rhumatologie, Angers, France

**Su-P413 EFFECT OF THREE DOSES OF STRONTIUM MALONATE (NB S101) ON MARKERS OF BONE TURNOVER AND BONE MINERAL DENSITY: THE STRONG STUDY**

K. Brixen<sup>1</sup>, K. Krosggaard<sup>2</sup>, S. Christgau<sup>3</sup>, M. Weis<sup>4</sup>, R. Eastell\*<sup>5</sup>  
<sup>1</sup>Dept of Endocrinology, Odense University Hospital, Odense, <sup>2</sup>PhaseOneTrials, Hvidovre Hospital, Hvidovre, <sup>3</sup>Research and development, <sup>4</sup>Clinical Development, Osteologix, Copenhagen, Denmark, <sup>5</sup>Metabolic Bone Centre, Sheffield University, Sheffield, United Kingdom

**Su-P414 DIETARY CALCIUM, PHOSPHORUS, PROTEIN AND BONE METABOLISM IN KOREAN POSTMENOPAUSAL WOMEN**

H. chung\*<sup>1</sup>, I. Jeong<sup>1</sup>, K. Ahn<sup>1</sup>, M. Kwon<sup>1</sup>, S. Rhee<sup>1</sup>, S. Chon<sup>1</sup>, S. Oh<sup>1</sup>, J. Woo<sup>1</sup>, S. Kim<sup>1</sup>, J. Kim<sup>1</sup>, Y. Kim<sup>1</sup>, H. Park<sup>2</sup>  
<sup>1</sup>Medicine, Kyung Hee University, <sup>2</sup>Obstetric and Gynecology, Chung-Ang University, Seoul, South Korea

**Su-P415 ACUTE AND CHRONIC EFFECTS OF PTH(1-84) TREATMENT ON HEART RATE AND CARDIAC REPOLARIZATION IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS**

J. Mason<sup>1</sup>, T. Moon<sup>1</sup>, S. Morris<sup>2</sup>, J. O. Clausen\*<sup>2</sup>  
<sup>1</sup>Covance, Reno, NV, United States, <sup>2</sup>International Medical Scientific Strategy and Medical Marketing, Nycomed, Roskilde, Denmark

**Su-P416 EARLY AND LATE CLINICAL AND INSTRUMENTAL RESULTS OF ADJUVANT THERAPY WITH TERIPARATIDE IN A SUBCLINICAL CASE OF OSTEOPOROTIC VERTEBRAL FRACTURES**

C. Corradini\*<sup>1</sup>, F. M. Olivieri<sup>2</sup>, C. Crapanzano<sup>3</sup>, C. A. Verdoia<sup>1</sup>  
<sup>1</sup>orthopaedic and traumatologic Clinic, Studies University of Milan, Orthopaedic Institute Gaetano Pini, <sup>2</sup>U.O. Nuclear Medicine, Fondazione IRCCS, <sup>3</sup>UO Clinical Pathology, Orthopaedic Institute Gaetano Pini, MILAN, Italy

**Su-P417 EFFECTS OF TERIPARATIDE ON DISTAL RADIAL FRACTURE HEALING IN POSTMENOPAUSAL WOMEN: A RANDOMIZED DOUBLE-BLINDED STUDY**

P. Aspenberg\*<sup>1</sup>, H. K. Genant<sup>2</sup>, T. Johansson<sup>1</sup>, A. J. Nino<sup>3</sup>, K. See<sup>3</sup>, K. Krohn<sup>3</sup>, P. Garcia<sup>4</sup>, C. P. Recknor<sup>5</sup>, T. A. Einhorn<sup>6</sup>, G. P. Dalsky<sup>7</sup>, M. Lakshmanan<sup>3</sup>  
<sup>1</sup>Linköping University, Linköping, Sweden, <sup>2</sup>Synarc INC and, UCSF, San Francisco, <sup>3</sup>Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, United States, <sup>4</sup>Depto de Endocrinologia, Hospital Universitario de Nuevo Leon, Monterey, Mexico, <sup>5</sup>, United

*Osteoporosis Centers, Gainesville, <sup>6</sup>, Boston Medical Center, Boston, <sup>7</sup>University of California, and Synarc Inc, San Francisco, United States*

**Su-P418 RELATIONSHIP BETWEEN SERIAL BIOCHEMICAL MEASUREMENTS AND BMD RESPONSE TO PARATHYROID HORMONE THERAPY**

S. de Bhaldrraith\*<sup>1</sup>, A. Pazderska<sup>1</sup>, K. Fitzgerald<sup>1</sup>, M. Healy<sup>2</sup>, J. B. Walsh<sup>1</sup>, M. Casey<sup>1</sup>  
*<sup>1</sup>Medicine for the Elderly, <sup>2</sup>Central Pathology Lab, St James Hospital, Dublin, Ireland*

**Su-P419 THE EFFECT OF PREVIOUS BISPHOSPHONATE USE ON BONE MINERAL DENSITY RESPONSE TO TREATMENT WITH PARATHYROID HORMONE**

S. de Bhaldrraith\*<sup>1</sup>, A. Pazderska<sup>1</sup>, K. Fitzgerald<sup>1</sup>, C. Walsh<sup>1</sup>, J. Walsh<sup>1</sup>, M. Casey<sup>1</sup>  
*<sup>1</sup>Medicine for the Elderly, St James Hospital, Dublin, Ireland*

**Su-P420 COMPARISON BETWEEN THE EFFECTS OF DAILY AND MONTHLY TREATMENT WITH IBANDRONATE IN OSTEOPENIC MALE RATS DUE TO ANDROGEN LACK**

M. Montero\*<sup>1</sup>, I. Quiroga<sup>2</sup>, S. Dapia<sup>3</sup>, J. Caeiro<sup>3</sup>, M. Rubert<sup>1</sup>, M. Diaz-Curiel<sup>4</sup>, F. Baus<sup>5</sup>, C. De la Piedra<sup>1</sup>

*<sup>1</sup>Osteoarticular Pathology Laboratory, Fundacion Jimenez Diaz, <sup>2</sup>Endocrinology, Hospital Puerta de Hierro, Madrid, <sup>3</sup>Trabeculae S.L., Parque Tecnoloxico de Galicia, Ourense, <sup>4</sup>Internal Medicine, Fundacion Jimenez Diaz, Madrid, Spain, <sup>5</sup>Pharma Research Penzberg, Roche Diagnostics GmbH, Penzberg, Germany*

**Su-P421 RESPONSIVENESS TO TERIPARATIDE IS GREATER IN PATIENTS PREVIOUSLY TREATED WITH RISEDRONATE THAN IN THOSE PREVIOUSLY TREATED WITH ALENDRONATE: THE OPTAMISE STUDY**

P. D. Delmas\*<sup>1</sup>, J. P. Bilezikian<sup>2</sup>, R. Lindsay<sup>3</sup>, N. B. Watts<sup>4</sup>, S. Boonen<sup>5</sup>, D. L. Cahall<sup>6</sup>, P. Miller<sup>7</sup>

*<sup>1</sup>INSERM Research Unit 831 and, Universite de Lyon, Lyon, France, <sup>2</sup>Division of Endocrinology, Metabolic Bone Diseases Unit, Columbia University College of Physicians and Surgeons, New York, <sup>3</sup>Regional Bone Center, Helen Hayes Hospital and Columbia University, West Haverstraw, <sup>4</sup>Director, University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati, United States, <sup>5</sup>Department of Experimental Medicine, Katholieke Universiteit Leuven, Leuven, Belgium, <sup>6</sup>Medical Affairs, sanofi-aventis, Bridgewater, <sup>7</sup>Director, Colorado Center for Bone Research, Lakewood, United States*

**Su-P422 BONE MINERAL DENSITY AND BIOCHEMICAL MARKER RESPONSE RATES IN POSTMENOPAUSAL WOMEN AFTER TREATMENT WITH ZOLEDRONIC ACID**

P. D. Delmas\*<sup>1</sup>, I. Reid<sup>2</sup>, R. Rizzoli<sup>3</sup>, S. Adami<sup>4</sup>, P. Sambrook<sup>5</sup>, E. F. Eriksen<sup>6</sup>, P. Mesenbrink<sup>7</sup>, R. Eastell<sup>8</sup>

*<sup>1</sup>INSERM Research Unit 831 and University of Lyon, University of Lyon, Lyon, France, <sup>2</sup>Department of Medicine, University of Auckland, Auckland, New Zealand, <sup>3</sup>WHO Collaborating Center for Osteoporosis Prevention, Geneva University Hospitals, Geneva, Switzerland, <sup>4</sup>Centro Ospedaliero Clinicizzato di Vallegio, University of Verona, Verona, Italy, <sup>5</sup>Department of Medicine, University of Sydney, Sydney, Australia, <sup>6</sup>Clinical Research and Development, Novartis Pharma AG, Basel, Switzerland, <sup>7</sup>Department of Biostatistics, Novartis Pharmaceuticals Corporation, New Jersey, United States, <sup>8</sup>Department of Human Metabolism*

*and Clinical Biochemistry, University of Sheffield, Sheffield, United Kingdom*

**Su-P423 BIPHOSPHONATE THERAPY AND HIP FRACTURES WITHIN THE RISEDRONATE AND ALENDRONATE (REAL) COHORT STUDY: SUBGROUP WITH PRIOR FRACTURE**

P. D. Delmas\*<sup>1</sup>, S. L. Silverman<sup>2</sup>, N. B. Watts<sup>3</sup>, J. L. Lange<sup>4</sup>, R. Lindsay<sup>5</sup>

<sup>1</sup>INSERM, Unit 403, Lyon, France, <sup>2</sup>, Cedars-Sinai Medical Center, Beverly Hills, CA, <sup>3</sup>Bone Health and Osteoporosis Center, Cincinnati, OH, <sup>4</sup>P&G, Pharmaceuticals, Mason, OH, <sup>5</sup>Helen Hayes Hospital, West Haverstraw, NY, United States

**Su-P424 EFFICACY OF 18 MONTHS TERIPARATIDE TREATMENT IN POSTMENOPAUSAL WOMEN WITH 2 OR MORE PRIOR VERTEBRAL FRACTURES AND A FEMORAL NECK FRACTURE: BMD, OCCURRENCE OF NEW FRACTURES AND BACK PAIN EVALUATION**

A. Di Francesco\*<sup>1</sup>, S. Flamini<sup>2</sup>

<sup>1</sup>Orthopaedic and Traumatology, Hospital S.Salvatore, L'Aquila, <sup>2</sup>Orthopaedic and Traumatology, Hospital S.Salvatore, L'Aquila, Italy

**Su-P425 EFFECTIVENESS OF ONE HOME VISIT BY AN OCCUPATIONAL THERAPIST IN THE PREVENTION OF FALLS: A QUASI-RANDOMIZED CONTROLLED TRIAL IN ELDERLY WOMEN WHO SUSTAINED A HIP FRACTURE**

M. Di Monaco\*<sup>1</sup>, F. Vallero<sup>1</sup>, E. De Toma<sup>2</sup>, L. De Lauso<sup>2</sup>, R. Tappero<sup>2</sup>, A. Cavanna<sup>1</sup>

<sup>1</sup>Osteoporosis Research Center, <sup>2</sup>Division of Physical Medicine and Rehabilitation, Presidio Sanitario San Camillo, Torino, Italy

**Su-P426 SERUM CALCIUM VALUES IN POSTMENOPAUSAL WOMEN WITH PRIMARY OSTEOPOROSIS AFTER ONE MONTH OF TREATMENT WITH PTH(1-84)**

M. Diaz-Curiel\*<sup>1</sup>, D. Hosking<sup>2</sup>, R. Rizzoli<sup>3</sup>, P. Delmas<sup>4</sup>, M. L. Brandi<sup>5</sup>, D. Felsenberg<sup>6</sup>, L. H. Hyldstrup<sup>7</sup>

<sup>1</sup>Servicio de Medicina Interna, Universidad Autonoma, Madrid, Spain, <sup>2</sup>David Evans Medical Research Centre, Nottingham City Hospital, Nottingham, United Kingdom, <sup>3</sup>Department of Rehabilitation and Geriatrics, University Hospital, Geneva, Switzerland, <sup>4</sup>Inserm, University Hospital, Lyon, France, <sup>5</sup>Department of Internal Medicine, Metabolic Unit, Firenze, Italy, <sup>6</sup>Charité - Campus Benjamin Franklin, Centre for Muscle and Bone Research, Free University and Humboldt University Berlin, Berlin, Germany, <sup>7</sup>International Medical Scientific Strategy and Medical Marketing, Nycomed, Roskilde, Denmark

**Su-P427 WOMEN LIVING IN NURSING/RESIDENTIAL HOMES: OSTEOPOROSIS TREATMENT, SURVIVAL AND INCIDENCE OF HIP AND OTHER FRACTURES**

M. N. Dugard<sup>1</sup>, T. Jones<sup>1</sup>, M. W. J. Davie\*<sup>1</sup>

<sup>1</sup>Charles Salt Research Centre, Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust, Oswestry, United Kingdom

**Su-P428 INTERACTION OF THE ACTIVE SITE THREONINE 201 SIDECHAIN WITH THE NITROGEN OF NITROGEN-CONTAINING BIPHOSPHONATES IS NOT ESSENTIAL FOR SLOW TIGHT INHIBITION TO FARNESYL PYROPHOSPHATE SYNTHASE**

J. E. Dunford\*<sup>1</sup>, E. Pilka<sup>2</sup>, A. A. Kwaasi<sup>1</sup>, A. Evdokimov<sup>3</sup>, B. L. Barnett<sup>3</sup>, U. Oppermann<sup>2</sup>, F. H. Ebetino<sup>4</sup>, R. G. Russell<sup>1</sup>, K. L. Kavanagh<sup>2</sup>

<sup>1</sup>*Nuffield Department of Orthopaedic Surgery*, <sup>2</sup>*Structural Genomics Consortium, Oxford University, Oxford, United Kingdom*, <sup>3</sup>*Dept. Chemistry, University of Cincinnati, Cincinnati*, <sup>4</sup>*New Drug Development, Procter & Gamble Pharmaceuticals, Mason, OH, United States*

**Su-P429 EFFICACY OF FOSAVANCE 5600® (ONCE WEEKLY ALENDRONATE 70 MG & VITAMIN D3 5600IU COMBINATION) RELATIVE TO RISEDRONATE 35MG WEEKLY FOR THE PREVENTION OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS: RESULTS OF A MIXED-TREATMENT INDIRECT COMPARISON META-ANALYSIS**

G. J. D. Bergman\*<sup>1</sup>, T. Fan<sup>2</sup>, S. S. Sen<sup>2</sup>, J. P. Jansen<sup>1</sup>

<sup>1</sup>, *Mapi Values, Houten, Netherlands*, <sup>2</sup>*Global Outcomes Research and HTA, Merck and Co., Inc, Whitehouse Station, United States*

**Su-P430 COST-EFFECTIVENESS OF ONCE WEEKLY ALENDRONATE PLUS VITAMIN D3 5600IU COMBINATON THERAPY IN THE PREVENTION OF FRACTURES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS BUT WITHOUT FRACTURE HISTORY IN THE NETHERLANDS**

G. J. D. Bergman\*<sup>1</sup>, T. Fan<sup>2</sup>, S. S. Sen<sup>2</sup>, J. P. Jansen<sup>1</sup>

<sup>1</sup>, *Mapi Values, Houten, Netherlands*, <sup>2</sup>*Global Outcomes Research and HTA, Merck and Co., Inc, Whitehouse Station, United States*

**Osteoporosis: treatment**

**See also: Mo-P431 - Mo-P469**

**Tu-P470 - Tu-P508**